Portland State University

PDXScholar

Dissertations and Theses

Dissertations and Theses

Spring 5-18-2015

Custom Fluorophores for Investigating the Cellular Uptake Mechanisms and Side-Effects of Pharmaceuticals

Yu-Hsuan Chu

Portland State University

Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds

Part of the [Chemicals and Drugs Commons](#), and the [Medicinal and Pharmaceutical Chemistry Commons](#)

Let us know how access to this document benefits you.

Recommended Citation

Chu, Yu-Hsuan, "Custom Fluorophores for Investigating the Cellular Uptake Mechanisms and Side-Effects of Pharmaceuticals" (2015). *Dissertations and Theses*. Paper 2343.

<https://doi.org/10.15760/etd.2340>

This Dissertation is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: pdxscholar@pdx.edu.

Custom Fluorophores for Investigating the Cellular Uptake Mechanisms and
Side-Effects of Pharmaceuticals

by

Yu-Hsuan Chu

A dissertation submitted in partial fulfillment of the
requirements for the degree of

Doctor of Philosophy
in
Chemistry

Dissertation Committee:
Robert M. Strongin, Chair
David Stuart
Erik Johansson
Jonathan J. Abramson

Portland State University
2015

ABSTRACT

There is a significant current need to elucidate the molecular mechanisms of the side-effects caused by widely-used pharmaceuticals. Examples include the acute nephrotoxicity and irreversible ototoxicity promoted by the cationic drugs gentamicin and cisplatin. Gentamicin is an aminoglycoside antibiotic used for the prevention and treatment of life-threatening gram-negative bacterial infections, such as tuberculosis and meningitis. Cisplatin is used to treat a broad spectrum of cancers including head and neck, ovarian, cervical, stomach, bladder, sarcoma, lymphoma, testicular cancer and others.

The objective of this study is to design and synthesize rhodamine derivatives that can be used for the construction of geometrically well-defined cationic drug conjugates. The long-term goal is to use the conjugates as tools to aid in elucidating the properties and identities of ion channels involved in the uptake of cationic pharmaceuticals into kidney and cochlear hair cells. This will shed light on the origin and potential prevention of unwanted side effects such as nephrotoxicity and ototoxicity associated with specific cationic drugs.

A series of extended rhodamine analogs with reactive groups for biomolecule conjugation has been synthesized. These fluorophores show similar spectral properties to their prototype, Texas Red succinimidyl ester (TR-SE). However, they contain rigid linkers between the fluorophore and amine-reactive moiety. The resultant gentamicin conjugates of these materials are rigidified enabling one to assess channel pore dimensions without the confounding issue of conjugate folding. Preliminary cell studies are promising, as one observes reduced gentamicin uptake in both kidney and sensory

hair cell upon systematically increasing the dimension of the fluorophore. This work has enabled us to tentatively assign the maximum dilated MET channel pore size as between 1.44 nm to 1.56 nm. However, this preliminary finding, though encouraging, needs further validation via ongoing studies with larger diameter fluorophore conjugates,

A cisplatin-Texas Red conjugate has also been synthesized to enable studies of cellular uptake mechanisms. This conjugate preserves not only the spectral properties of Texas Red after conjugation, but also the cytotoxicity of cisplatin. This has been validated in zebrafish. The series of rhodamine probes that have been conjugated to gentamicin should be similarly useful for cisplatin studies. These studies are planned. Additional future work includes the synthesis of semi-flexible (glycol) and flexible (alkyl) linkers to evaluate structure-activity relationships.

ACKNOWLEDGEMENTS

I have gained so much help and support from many individuals along the Ph.D. journey. Without their time, attention and thoughtful feedback, I would not be able to accomplish this incredible adventure.

First of all, I am deeply thankful to my advisor, Prof. Robert M. Strongin for his great motivation, advice and care. He has been patient and encouraging to students with new ideas and key insights. He is the one showing me how to be a great chemist. Also, I would like to express my appreciation to Dr. Martha Sibrian-Vazquez, Dr. Jorge O. Escobedo, Dr. Mark Lowry and Dr. Joseph Rajan for their guidance and assistance on my research project. It has been my honor to work and learn with them.

I would like to extend my gratitude to committee members, Prof. Erik Johansson, Prof. David Stuart, Prof. Jonathan J. Abramson and Prof. Reuben H. Simoyi for their constructive comments and suggestions. And special thanks to Prof. Peter S. Steyger and Meiyang Jiang, our collaborators from Oregon Health & Science University. It's been a privilege to cooperate with them.

I want to thank my colleagues, Jialu Wang, Lei Wang, Aabha Barve and Lovemore Hakuna, over the past five years, for their company and bonds of friendship. In addition, to my best friend and soul mate, Chieh Hsu, thanks for his spiritual support, encouragement and sharing the unforgettable memories with me.

Last but not least, I would like to thank my family, my Dad Lucas Chu, my Mom Ling-Hue Su and my brother Leo Chu. Without their unconditional love and support, I wouldn't be the person I am today.

TABLE OF CONTENTS

ABSTRACT.....	i
ACKNOWLEDGEMENTS.....	iii
LIST OF TABLES	vii
LIST OF FIGURES	viii
LIST OF ABBREVIATIONS.....	xi
CHAPTER 1 INTRODUCTION	1
1.1 Gentamicin	1
1.2 Bactericidal mechanism of gentamicin	2
1.3 Trafficking routes of gentamicin into the cochlea associated with deafness	3
1.4 Cisplatin	4
1.5 Mechanism of action of Cisplatin	5
1.6 Trafficking routes of cisplatin into hair cells	6
CHAPTER 2 DESIGN, SYNTHESIS AND CHARACTERIZATION OF CONJUGATABLE RHODAMINE ANALOGS	8
2.1 Introduction	8
2.2 Molecular shape modifications of rhodamine analogs.....	9
2.3 Synthetic strategies of rhodamine analogs	13
2.3.1 Synthesis of inflexible Texas Red, 2.6	14
2.3.1 Synthesis of inflexible rhodamine, 2.7	15

2.3.2 Synthesis of inflexible rhodamine, 2.8	18
2.4 Spectral properties.....	23
2.5 Experimental section.....	28
Material and Methods	28
2.6 Conclusion.....	43
2.7 Future Work	44
CHAPTER 3 THE UTILITY OF RIGID FLUOROPHORE-GENTAMICIN CONJUGATES IN ZEBRAFISH AND KIDNEY CELL TRAFFICKING STUDIES...	45
3.1 Introduction	45
3.2 Synthesis of gentamin conjugates	45
3.3 Cell Imaging Studies	47
3.3.1 MDCT cell	47
3.3.2 Zebrafish	48
3.4 Experimental Section	50
3.5 Conclusion.....	51
3.6 Future	52
CHAPTER 4 SYNTHESIS OF A CISPLATIN-TEXAS RED CONJUGATE	53
4.1 Introduction	53
4.2 Synthetic strategies of cisplatin conjugates.....	55

4.2.1 Synthesis of cisplatin-fluorescein conjugate, 4.2	55
4.2.2 Synthesis of cisplatin-Texas Red conjugate, 4.1	57
4.3 Spectral properties.....	60
4.4 Cellular studies	61
4.5 Experimental section	64
Material and Methods	64
4.6 Conclusion.....	67
4.7 Future Work	68
CHAPTER 5 SYNTHESIS OF A TETRAAMINO PLATINUM-TEXAS RED CONJUGATE.....	69
5.1 Introduction	69
5.2 Synthesis of a tetra-amino platinum complex and its Texas Red Conjugate	70
5.3 Conclusion and future work	72
REFERENCES	73
APPENDIX A: ^1H NMR, ^{13}C NMR AND MS SPECTRA FOR SELECTED COMPOUNDS FROM CHAPTER 1	79
APPENDIX B: ^1H NMR, ^{13}C NMR, ^{195}Pt AND MS SPECTRA FOR SELECTED COMPOUNDS FROM CHAPTER 4.....	102

LIST OF TABLES

Table 2.1 Comparison of the fluorescence properties of compounds 2.2, 2.6, 2.7 and 2.8	25
Table 4.1 Retention times and peak areas for each isomer.....	60

LIST OF FIGURES

Figure 1.1 Gentamicin isomers	2
Figure 1.2 The mechanism of aminoglycoside binding to bacteria and the induction of cell death. Aminoglycosides bind to the 30s subunit of the ribosome causing misfolded proteins to be synthesized. Misfolded membrane proteins lead to enhanced drug uptake and cell death. The figure was adapted from Kohanski <i>et al.</i>	3
Figure 1.3 Potential trafficking routes of gentamicin entering cochlea.	4
Figure 1.4 Cisplatin.....	5
Figure 1.5 Aquation of cisplatin and insertion into DNA helical structure.	6
Figure 1.6 The trans-strial trafficking pathway for cisplatin from stria vascularis.	7
Figure 2.1 Aminoglycosides labeling reagents and structures.....	9
Figure 2.2 Isomers of Gentamicin-Texas Red conjugate (GTTR, 2.1) and Texas Red succinimidyl ester (TR-SE, 2.2).....	9
Figure 2.3 Phosphatidylinositol 4, 5-bisphosphate (PIP ₂)	10
Figure 2.4 Molecular simulations of 2.1, showing that the flexible linker promotes the interaction between fluorophore and gentamicin.....	11
Figure 2.5 Molecular simulations of rhodamine analogs conjugated with gentamicin. ...	13
Figure 2.6 Designed fluorophores for conjugation to gentamicin	14
Figure 2.7 Proposed Inflexible Texas-Red, 2.6	14
Figure 2.8 Proposed extended inflexible rhodamine, 2.7	15
Figure 2.9 Designed extended-inflexible fluorophore with additional [1,2]-butano fused rings 2.8 and 2.22.....	18

Figure 2.10 Retrosynthetic strategy for synthesis of compound 2.22.....	19
Figure 2.11 Retrosynthetic strategy for the synthesis of compound 2.8.....	20
Figure 2.12 An alternative retrosynthetic strategy for attaining compound 2.32	22
Figure 2.13 Absorption spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 μ M. Solvent: MeOH	25
Figure 2.14 Normalized fluorescence excitation spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 μ M. Solvent: MeOH	26
Figure 2.15 Normalized fluorescence emission spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 μ M. Solvent: MeOH	26
Figure 2.16 Absorption spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 μ M. Solvent: PBS:DMSO 9:1	27
Figure 2.17 Normalized fluorescence excitation spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 μ M.....	27
Figure 2.18 Normalized fluorescence emission spectra of 2.2, 2.6, 2.7 and 2.8. Probe concentration: 1.25 μ M. Solvent: PBS:DMSO 9:1.....	28
Figure 3.1 Fluorophores-gentamicin conjugates.....	46
Figure 3.2 Cellular uptake of MDCT cells.	47
Figure 3.3 Cellular uptake with 1 μ g/ml conjugates and free fluorophores by wild-type and mariner zebrafish.....	49
Figure 4.1 Fluorophores have been conjugated with cisplatin and its structure	54
Figure 4.2 Isomers of Cisplatin-Texas Red conjugate, 4.1 and fluorescein conjugate, 4.2	55

Figure 4.3 HPLC trace of compound 4.6 (isomer mixture).....	57
Figure 4.4 HPLC trace of compound 4.2(isomer mixture).....	57
Figure 4.5 Texas Red succinimidyl ester isomers	59
Figure 4.6 HPLC trace of compound 2.2 (isomer mixture).....	59
Figure 4.7 HPLC trace of compound 4.1 (isomer mixture).....	59
Figure 4.8 Absorption spectra of 1.25 μ M of 4.1 and 2.2 in MeOH.	61
Figure 4.9 Excitation/Emission fluorescence spectra of 1.25 μ M of 4.1 and 2.2 in MeOH.	61
Figure 4.10 Comparison of DDP-Fl (A) and DDP-TR (B) uptake by MDCK cells.	62
Figure 4.11 Cytotoxicity in zebrafish neuromast hair cells with a range of dose.....	63
Figure 5.1 Carboplatin	69
Figure 5.2 Amino platinum complex 5.1 and its proposed Texas Red conjugate 5.2	70

LIST OF ABBREVIATIONS

AcOH	Acetic Acid
AGs	Aminoglycosides
aq	aqueous
Ar	Argon gas
ATP7A	Copper transporting ATPase 1
Boc	<i>tert</i> -butyloxycarbonyl
CFDA-SE	5(6)-carboxyfluorescein diacetate succinimidyl ester
CH₂Cl₂	Dichloromethane
Ctrl	Copper transporter-1
DCE	Dichloroethane
DDP-FI	Cisplatin-fluorescein conjugate
DDP-TR	Cisplatin-Texas Red conjugate
DI	Deionized
DMF	N,N-dimethylformamide
DMSO	Dimethylsulfoxide
DNA	Deoxyribonucleic acid
EDAC	1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
Equiv	Equivalents
ESI MS	Electrospray ionization mass spectrum
Et₂O	Ethyl ether
Et₃N	Triethylamine

EtOAc	Ethyl acetate
GTTR	Gentamicin Texas Red conjugate
h	hour
HBr	Hydrobromic acid
HCl	Hydrochloric acid
HPLC	High performance liquid chromatography
iTR	Inflexible Texas Red
KOH	Potassium hydroxide
LC/MS	Liquid chromatography–mass spectrometry
LiAlH₄	Lithium aluminium hydride
MDCK	Madin-Darby Canine Kidney
MDCT	Mouse Distal Convoluted Tubule
MeCN	Acetonitrile
MeI	Methyl iodide
MeOH	Methanol
MET	Mechanoelectrical
min	minutes
MS	Mass Spectrometry
NaBH(OAc)₃	Sodium triacetoxyborohydride
NaBH₄	Sodium borohydride
NHS	<i>N</i> -Hydroxy succinimide
NMR	Nuclear magnetic resonance

Oct2	Organic cation transporter 2
PBr₃	Phosphorus tribromide
PBS	Phosphate-buffered saline
PIP₂	Phosphatidylinositol 4, 5-bisphosphate
PLs	Phospholipids
PPA	Polyphosphoric acid
RNA	Ribonucleic acid
ROS	Reactive oxygen species
rt	Room temperature
s	seconds
SN₂	Second-order Nucleophilic Substitution
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
TMS	Tetramethylsilane
TRPV1	Transient receptor potential cation channel subfamily V member 1
TRPV4	Transient receptor potential cation channel subfamily V member 4
TR-SE	Texas Red succinimidyl ester
UV-Vis	Ultraviolet-visible
Zn	Zinc

CHAPTER 1 INTRODUCTION

Most medications, regardless of whether they are of the over-the-counter or prescription variety, exhibit a certain level of undesirable and sometimes life-threatening side-effects. Two examples of widely-prescribed drugs that cause profound side effects in extremely high percentages of the patients using them are gentamicin and cisplatin. Although they possess very dissimilar structures and treat different diseases, each causes acute renal dysfunction and irreversible hearing loss.

1.1 Gentamicin

Gentamicin, a major aminoglycoside antibiotic naturally produced by *Micromonospora*, is composed of three major isomeric components C₁, C_{1a} and C₂, as shown in Figure 1.1. It is used in the treatment of gram-negative infections such as tuberculosis,¹ meningitis,² cystic fibrosis,³ and in the prevention of sepsis infections in burn patients⁴ and premature babies.⁵ However, irreversible ototoxicity and acute nephrotoxicity are serious side effects in patients. Every year > 600,000 new-born babies receive gentamicin for a diagnosis of potential sepsis.⁵ Over 10% of all patients that receive aminoglycoside antibiotics suffer from drug-induced hearing loss.⁶ The lifetime opportunity cost for hearing impairment was estimated at \$1 million in 2000 for each pre-lingual deaf child.⁷ Approximately 14% of all patients receiving gentamicin treatment also experience acute loss of kidney function.⁶ Despite these risks, gentamicin is a clinically-essential antibiotic due to its high bactericidal efficacy and low cost.⁸

Figure 1.1 Gentamicin isomers

1.2 Bactericidal mechanism of gentamicin

Aminoglycosides (AGs) such as gentamicin irreversibly bind to the 30s subunit of the bacterial ribosome responsible for protein synthesis. Binding triggers a cascade of events leading to cell death, beginning with altered protein biosynthesis, due to the misincorporation of amino acids into elongating peptides. The resulting proteins are often misfolded and dysfunctional. When incorporated into the cytoplasmic membrane, misfolded proteins enhance the permeability of the cell membrane, thereby further enhancing gentamicin uptake and toxicity. Mistranslated bacterial membrane proteins additionally disrupt the signaling mechanism that counteracts the cytotoxicity of AGs as well as β -lactam antibiotics, leading to the synergistic bactericidal efficacy of the two compounds.⁹

Figure 1.2 The mechanism of aminoglycoside binding to bacteria and the induction of cell death. Aminoglycosides bind to the 30s subunit of the ribosome causing misfolded proteins to be synthesized. Misfolded membrane proteins lead to enhanced drug uptake and cell death. The figure was adapted from Kohanski *et al.*⁹

1.3 Trafficking routes of gentamicin into the cochlea associated with deafness

Many studies have focused on the intracellular mechanisms of unwanted side-effects of AGs in the kidney and cochlear sensory hair cells in the inner ear. However, the precise route of drug trafficking from the vasculature across the blood-labyrinth barrier and into sensory hair cells in the inner ear is still not completely understood. Aminoglycosides could enter hair cells via various mechanisms (Figure 1.3, route 1) including apical endocytosis¹⁰⁻¹² and via ion channels such as the mechanoelectrical (MET) transduction channel¹³ on the apical surface of the cochlear hair cells. This indicates that the most viable route for systemically-administered AGs *in vivo* is believed to take place via passage from the stria capillaries into the endolymph (trans-stria trafficking mechanism) prior to entering hair cells through MET channels, as shown in Figure 1.3, route 2.^{13,14} There are potential alternative trafficking pathways that AGs could take prior to entering hair cells, such as via capillaries in the spiral ligament of the

lateral wall into the perilymph of the scala tympani and across the baso-lateral membrane of hair cells. (Figure 1.3, route 3 and 4).

Figure 1.3 Potential trafficking routes of gentamicin entering cochlea.

(Route 1) Aminoglycosides are known to enter hair cells via apical endocytosis or permeation of the MET channels on the apical surface of hair cells. (Route 2) AGs could enter the endolymph via a trans-strial trafficking route from stria capillaries to marginal cells, or (Route 3) by traversing the blood labyrinth barrier into perilymph and then (Route 4) into hair cells across their baso-lateral membranes (diagram not to scale). This figure was adapted from Wang *et al.*¹⁵

1.4 Cisplatin

Cisplatin (*cis*-diamminedichloroplatinum[II]) is a platinum-containing anti-cancer drug, whose bioactivity was discovered by Rosenberg *et al.* in 1965.¹⁶ Since then, cisplatin has become a cornerstone of antineoplastic chemotherapy to treat many types of cancer, including ovarian, cervical, stomach, bladder, head and neck.¹⁷⁻¹⁹ Cisplatin is especially efficacious for testicular cancer, wherein over 90% of cases enter remission

after treatment.²⁰ Every year more than one million patients receive cisplatin or its derivatives in North America and Europe. Unfortunately, the clinical use of cisplatin is limited by acquired drug resistance and severe dose-dependent side effects, such as ototoxicity and nephrotoxicity (similar to gentamicin, above). Clinical studies show that > 60% of patients taking multiple doses of cisplatin will develop permanent hearing loss^{21,22} and acute renal dysfunction.²³ Drug-induced hearing loss can severely affect an individual's quality of life. Consequences can include social isolation, depression and loss of income. Children can exhibit delayed development of communication and learning skills, and have a relatively challenging time developing social interactions.^{21,22} Therefore, an understanding of the fundamental biological mechanisms that lead to cisplatin-induced ototoxicity and nephrotoxicity can have a profound impact on patients' lives, especially if it can inform the development of less harmful therapeutic options, or the development of otoprotective strategies.

Figure 1.4 Cisplatin

1.5 Mechanism of action of Cisplatin

During chemotherapy, cisplatin binds to DNA, disrupting genetic function and selectively killing rapidly proliferating cells such as cancer cells. The underlying mechanism involves ligand exchange within the cells of cisplatin's chlorides for H₂O, in a process called aquation. These charged aquated complexes are highly reactive and bind

to the N⁷ position of purines on DNA, forming cisplatin-DNA adducts, distorting the helical structure of DNA (Figure 1.5).²⁴ Cells identify this as damaged DNA, activating several signaling cascades that induce cell cycle arrest and apoptosis.²⁵

Figure 1.5 Aquation of cisplatin and insertion into DNA helical structure.

Oxidative stress is thought to be another major mechanism of cisplatin-induced ototoxicity and nephrotoxicity.²⁶ Once cisplatin enters cells, the charged aquated-platinum complex rapidly interacts with thiol-containing antioxidant molecules such as glutathione and methionine.²⁷ The depletion of antioxidants leads to cytotoxic levels of reactive oxygen species (ROS) and lipid peroxidation product accumulation in cells. Other mechanisms whereby cisplatin promotes elevated levels of ROS are via the respiratory chain²⁸ and the cytochrome P450 (CYP) system²⁹.

1.6 Trafficking routes of cisplatin into hair cells

As shown in Figure 1.6, cisplatin has an uptake route into cochlear hair cells analogous to that described above for gentamicin, entering the endolymph via a trans-

strial trafficking route from stria vascularis (route 2). To date, several studies have shown that one or several candidate membrane transporters potentially play an important role in cisplatin uptake and efflux pathways to induce cytotoxicity, and cochleotoxicity (hearing loss). These include the copper transporters (Ctr1 and ATP7A) and the organic cation transporter (Oct2).³⁰⁻³² Ciarimboli *et al.*³³ using a Oct2 inhibitor, cimetidine, and More *et al.*³⁴ using the competitive inhibitor, CuSO₄, have observed protection from cisplatin-inducing hearing loss *in vivo*, as further evidence of the involvement of Oct2 and Ctr1 in cisplatin uptake into healthy cells. However, results reported by Thomas *et al.* using a rhodamine-cisplatin conjugate showed that MET channel function is required for cisplatin-induced hair cell cytotoxicity, while Ctr1 and Oct2 are not involved in the cisplatin uptake mechanism.³⁵ In other words, there is a significant current need to clarify the mechanism of cisplatin entry into cochlear hair cells.

Figure 1.6 The trans-strial trafficking pathway for cisplatin from stria vascularis. The candidate cisplatin transporters are located on the strial capillaries including Oct2, Ctr1 and ATP7A (M, marginal cell; I, intermediate cell; B, basal cell; E, endothelial cell) (diagram not to scale).

CHAPTER 2 DESIGN, SYNTHESIS AND CHARACTERIZATION OF CONJUGATABLE RHODAMINE ANALOGS

2.1 Introduction

Fluorescent probes are widely used for the detection of specific biomolecular pathways and cellular events. The objective of this study is to synthesize rigid, geometrically well-defined rhodamine derivatives to serve as the optical components of cationic drug-fluorophore conjugates. The long-term goal is to use these drug-fluorophore conjugates to determine the dimensions of ion channels involved in the cellular uptake of pharmaceuticals such as gentamicin. This is significant because new information on cellular trafficking can shed light on the mechanism, and potential prevention of side effects such as ototoxicity and nephrotoxicity.

Fluorescein, BODIPY and acridine dyes (Figure 2.1) have been conjugated to aminoglycosides such as gentamicin and neomycin to study cellular uptake,^{36,37} HIV-RNA binding³⁸ and for use in fluorescent immunoassays.³⁹ The fluorescent conjugate of gentamicin and Texas Red (GTTR, **2.1**) has been of great utility in the study of non-endocytotic aminoglycoside uptake and intracellular localization (Figure 2.2).^{40,41} Texas Red succinimidyl ester (TR-SE, **2.2**) is the fluorophore used for gentamicin conjugation because it imparts amphiphilic properties, cationic charge and enables the retention of drug bioactivity.⁴²⁻⁴⁴

Figure 2.1 Aminoglycosides labeling reagents and structures

Figure 2.2 Isomers of Gentamicin-Texas Red conjugate (GTTR, **2.1**) and Texas Red succinimidyl ester (TR-SE, **2.2**)

2.2 Molecular shape modifications of rhodamine analogs

GTTR *in vivo* studies have been mainly performed in fixed cells since live cells quench GTTR fluorescence.⁴⁰ This fluorescence quenching has been attributed in part to the interactions between gentamicin and phospholipids. It has been reported that cationic

aminoglycosides have high affinity for the anionic phospholipid phosphatidylinositol 4, 5-bisphosphate (PIP₂, Figure 2.3).^{45,46} GTTR fluorescence quenching in cells was determined by Myrdal *et al.* Results from these studies indicate that gentamicin binding to PIP₂ and similar phospholipids (PLs) is likely responsible for quenching GTTR fluorescence in live cells and that this quenching can be unmasked by delipidating cells using either Triton-X 100 or similar delipidating agents.⁴⁰

Figure 2.3 Phosphatidylinositol 4, 5-bisphosphate (PIP₂)

Molecular modeling was used to guide the design of new fluorophores for conjugation to gentamicin to allow the study of gentamicin cellular uptake trafficking in live and fixed cells. Simulations showed that the current GTTR conjugate, **2.1** used in preliminary studies, has a sulfonated-flexible linker between the gentamicin and Texas Red moieties that promotes folding of the structure and interactions between the fluorophore and gentamicin. (Figure 2.4)

Figure 2.4 Molecular simulations of **2.1**, showing that the flexible linker promotes the interaction between fluorophore and gentamicin

Also, the energy-minimized structure of stretched conformer of GTTR (Figure 2.5A) has a maximal cross-sectional diameter of 1.35 nm, and can pass through cation-selective channels on hair cell stereocilia, such as MET channels,¹³ TRPV1⁴⁷ and TRPV4,⁴⁸ likely through pore dilation.⁴⁹ MET channels have a minimum pore size of 1.25 nm⁵⁰; TRPV1 channels have an open pore size of ~1 nm^{51,52} that increases following agonist-induced pore dilation,^{49,53} TRPV4 channels have a larger pore diameter⁵⁴ that allows organic cation permeation upon agonist-induced activation.⁵⁵

Because of the correlation between the molecular simulations and the results of preliminary studies using the current gentamicin conjugate **2.1**, it is hypothesized that rigidifying the linker will avoid potential intramolecular interactions between the fluorophore and gentamicin, and thereby inhibit fluorescence quenching. In addition, the

incorporation of a rigid linker will prevent conjugate bending as a means of passing through ion channels, and thus act as a molecular ruler of channel pore diameter.

In order to test the hypothesis that systematic molecular shape modifications of the fluorophore and linker can afford control over hair cell and kidney cell gentamicin uptake and toxicity, a series of inflexible rhodamine analogs were designed and synthesized. Molecular simulations show that a biaryl linker (**2.3**, Figure 2.5B) meets the requirement to prevent intramolecular interactions between the fluorophore and the gentamicin moieties, and possesses a cross-sectional diameter of 1.44 nm. The cross-sectional diameter of the final conjugate can be increased to 1.56 nm by adding four methyl groups to the fluorophore scaffold (**2.4**, Figure 2.5C). Additional [1,2]-butanofused rings on the fluorophore framework furnishes a conjugate with a cross-sectional diameter of 1.85 nm (**2.5**, Figure 2.5D). The design of these rigid probes allow them to be used as molecular rulers, to aid us in determining the maximum diameter of dilated AG-permissive ion channels, such as MET channel and TRPV1.

Figure 2.5 Molecular simulations of rhodamine analogs conjugated with gentamicin. (A) Flexible GTTR, yellow atoms represent sulfur atoms. (B) Sulfur atoms are replaced by para-phenyl rings, to give inflexible conjugates. (C, D) Adding methyl groups or [1,2]-butano fused rings increases the diameter of the conjugate.

2.3 Synthetic strategies of rhodamine analogs

Figure 2.6 shows the three fluorophore structures that were proposed from the simulations. The figure shows the inflexible biaryl linkers of each, as well as the extended cross-sectional diameter of the fluorophore.

Figure 2.6 Designed fluorophores for conjugation to gentamicin

2.3.1 Synthesis of inflexible Texas Red, 2.6

Figure 2.7 Proposed Inflexible Texas-Red, 2.6

Based on the molecular simulation results, inflexible Texas Red analog **2.6** possesses a diameter of 1.44 nm. As shown in scheme 2.1, compound **2.6** was synthesized in four steps with an overall yield of 13%. The initial step involves the condensation of 8-hydroxyjulolidine **2.9** and 4-bromobenzaldehyde **2.10** under microwave conditions followed by addition of *p*-chloranil as an oxidant to give bromo-substituted rhodamine **2.11** in 47%.⁵⁶ Suzuki-coupling of **2.11** with 4-(*N*-Boc-amino) phenylboronic acid was carried out in the presence of K_2CO_3 in MeOH, heated at reflux

overnight to afford Boc-protected amino biphenyl Texas-Red **2.12** in 45%. Removal of the Boc group using trifluoroacetic acid gave the free amine **2.13**,⁵⁷ which was reacted with 1,1'-thiocarbonyldi-2(1*H*)-pyridine to afford **2.6** in 71% yield.⁵⁸

Scheme 2.1 Synthesis of inflexible Texas Red, **2.6**

2.3.1 Synthesis of inflexible rhodamine, **2.7**

Figure 2.8 Proposed extended inflexible rhodamine, **2.7**

Rhodamine **2.7** possesses four methyl groups on the fluorophore scaffold resulting in a diameter of 1.56 nm. As shown in scheme 2.2, the required hydroxyl-quinoline **2.17** was synthesized using a modified procedure as described by Belov *et al.*⁵⁹ Trimethyl-dihydroquinoline amine **2.15** was obtained in 80% yield by condensation of *m*-anisidine with acetone at rt for 24 h using ytterbium triflate as the catalyst. Further alkylation of **2.15** with methyl iodide in the presence of cesium carbonate gave the tetramethyl-dihydroquinoline **2.16** in 89% yield. Nucleophilic dealkylation of intermediate **2.16** with 48% aq. HBr in acetic acid gave the corresponding hydroxyl-quinoline **2.17** in 54% yield.

Scheme 2.2 Synthesis of hydroxyl-quinoline precursor **2.17**

As shown in scheme 2.3, initial attempts (Route 1) to prepare the succinimidyl activated ester **2.7** involved the synthesis of the bromo-substituted rhodamine **2.18** published by Jiao *et al.*⁵⁶ followed by a Suzuki coupling reaction with (4-(methoxycarbonyl)phenyl)boronic acid.⁶⁰ After extensive optimization, the Suzuki coupling reaction of bromo-substituted rhodamine with boronic acid gave precursor **2.19**; however, the reaction was sluggish (it required five days) and gave rise to mixtures hard to separate. Therefore, an alternative approach (Route 2) involving the direct condensation of the hydroxyl-quinoline **2.17** and methyl 4-(4-formylphenyl)benzoate **2.20** was evaluated. The methyl ester precursor **2.19** was obtained in 67 % yield by

condensation of hydroxy-quinoline **2.17** and methyl 4-(4-formylphenyl)benzoate **2.20** under microwave conditions in the absence of solvent at 150 °C followed by oxidation with *p*-chloranil. The hydrolysis of methyl ester intermediate **2.19** was conducted under basic conditions using LiOH in a mixture of MeOH:THF:H₂O (5:3:1) to give compound **2.21** in 78%. The activated succinimidyl ester **2.7** was achieved in 84% yield using EDAC as the coupling reagent. The target fluorophore **2.7** was synthesized in six steps with an overall yield of 17%.

Route 1

Route 2

Scheme 2.3 Synthesis of compound **2.7**

2.3.2 Synthesis of inflexible rhodamine, 2.8

Figure 2.9 Designed extended-inflexible fluorophore with additional [1,2]-butano fused rings **2.8** and **2.22**

Two extended inflexible Texas Red with additional [1,2]-butano fused rings on the fluorophore scaffold are shown in Figure 2.9. While compound **2.8** fulfills the proposed architectural goals, compound **2.22** with its additional cyano groups is also of interest. The cyano substituents may positively influence the spectra properties such as enhancing quantum yield. Retrosynthetic analysis of compound **2.22** (Figure 2.10) was envisioned as including the condensation of cyano-hydroacridinol **2.23** and commercial available methyl 4-(4-formylphenyl)benzoate **2.20**, using similar reaction conditions as described above for the synthesis of compound **2.19**. Therefore, in order to accomplish the goal to synthesize the cyano-hydroacridinol **2.23**, a divergent route was pictured as incorporating the ring opening of aziridine **2.27** by nucleophilic substitution with bromophenyl acetonitrile **2.24** followed by Pd-catalyzed intramolecular C-N cycloaddition.⁶¹ Bromophenyl acetonitrile **2.24** can be synthesized from aldehyde **2.26** via reduction and bromination followed by substitution with cyanide. Aziridine **2.27** can

be synthesized via a Mitsunobu reaction using ring-opened epoxide **2.28**. The overall synthesis of cyano-hydroacridinol **2.23** is shown in Scheme 2.4.

Figure 2.10 Retrosynthetic strategy for synthesis of compound **2.22**

As shown in Scheme 2.4, benzyl bromide **2.25** was synthesized in two steps by using procedures as described previously by Bower *et al.*⁶² Reduction of aldehyde **2.26** afforded alcohol **2.29** in near quantitative yield with NaBH_4 . Alcohol **2.29** was brominated with PBr_3 at 0°C to afford benzyl bromide **2.25** in 95% yield. Cyanide **2.24** was added via an $\text{S}_{\text{N}}2$ reaction in 83% yield.⁶³ Aziridine **2.27** was prepared in two steps as described by Shen *et al.*⁶⁴ β -amino alcohol **2.30** was synthesized via nucleophilic addition of methyl amine to epoxide **2.28** in 100% yield. However, the ring-closure of amino alcohol under Mitsunobu reaction conditions provided only a trace amount of

aziridine **2.27**. It proved hard to purify and obtain in good yield, as multiple components were observed in the crude product mixture.

Scheme 2.4 Synthesis of precursor **2.24** and **2.27**

Retrosynthetic analysis (Figure 2.11) of decahydroquinoline **2.8** was envisioned as occurring via the condensation of hydroacridinol **2.32** and the commercial available **2.20**, using similar reaction conditions as described above for the synthesis of compound **2.19**. Decarboxylative cycloaddition of isatoic anhydride **2.35** to cyclohexene **2.36** would form acridione **2.34**. Reduction of the ketone and dealkylation of the methoxy group would furnish desired intermediate **2.32**.

Figure 2.11 Retrosynthetic strategy for the synthesis of compound **2.8**

Isatoic anhydride **2.39** was synthesized using a modified version of a procedure described by Acker *et al.*⁶⁵ This approach involved two additional eliminations from anthranilic acid **2.37** reacting with triphosgene **2.38** under reflux condition to give isatoic anhydride **2.39** in 95% yield (Scheme 2.5). Alkylation of isatoic anhydride **2.39** with methyl iodide gave the corresponding *N*-methyl isatoic anhydride **2.35** in 93% yield.⁶⁶ In order to obtain intermediate **2.34**, nickel-catalyzed decarboxylative cycloaddition of isatoic anhydride **2.35** with cyclohexene **2.36** was investigated using the procedure described by Sun *et al.*⁶⁷ Zinc was prepared and activated using a protocol described by Vogel *et al.*,⁶⁸ or commercially available Rieke Zinc. However, all attempts to produce the cycloaddition product **2.34** using either freshly prepared activated Zn or commercially available Rieke Zinc were unsuccessful. ESI MS analysis showed that a mass corresponding to an intermediate of the target compound **2.34** was present in the crude mixture. However the mass corresponding to **2.34** was not found and numerous TLC spots were observed when analyzing the product mixture.

Scheme 2.5 Synthesis of intermediate **2.34**

After several failed attempts to synthesize hydroacridinol **2.32**, an alternative approach, involving no previously-reported intermediates, was designed as shown in Scheme 2.6. The retrosynthetic analysis is shown in Figure 2.12. It is envisioned a Friedel-Crafts acylation of **2.40** followed by reduction and dealkylation to afford target **2.32**. Forging the C-C bond through intramolecular from *N*-phenylcarboxylic acid **2.40** to form hydroacridinone **2.34**. *N*-phenylcarboxylic acid **2.40** would be derived from reductive amination via the reaction of aniline **2.41** and β -ketoester **2.42**.

Figure 2.12 An alternative retrosynthetic strategy for attaining compound **2.32**

As shown in Scheme 2.6, the reductive amination of aniline **2.41** and β -ketoester **2.42** with $\text{NaBH}(\text{OAc})_3$ affords product **2.43** in 69% yield.⁶⁹ Alkylation of **2.43** with MeI gives the corresponding *N*-methylated product **2.44** in 80% yield. Compound **2.44** was hydrolyzed under basic conditions at rt to afford **2.40** in 99%. After reaction optimization, the cyclization of hydroacridinone **2.40** in polyphosphoric acid (PPA) led to hydroacridinone **2.34** in a low yield of 16% via intramolecular Friedel-Crafts acylation.⁷⁰ Reduction of hydroacridinone **2.34** using LiAlH_4 under reflux conditions gave the corresponding acridine **2.33** in 90%.⁷¹ The target intermediate hydroacridinol **2.32** was successfully obtained in 99% yield by nucleophilic dealkylation of the methoxy ether using 48% aq. HBr. The target compound **2.8** was synthesized in three steps using a similar strategy as described above for extended Texas Red **2.7**, which involves the

condensation of hydroacridinol **2.32** and methyl 4-(4-formylphenyl)benzoate **2.20** in 49% yield, and basic hydrolysis of the methyl ester **2.45** gave **2.46** in 99% yield. The activated succinimidyl ester **2.8** was obtained in 85% yield using EDAC as the coupling reagent.

Scheme 2.6 Synthesis of compound **2.8**

2.4 Spectral properties

In order to determine that the new fluorophores have the similar spectral properties as compared to the parent probe TR-SE (**2.2**), the absorbance and fluorescence

spectra of 1.25 μ M solution of compound **2.2**, **2.6**, **2.7** and **2.8** were evaluated in organic solvent (MeOH) and buffer (PBS:DMSO 9:1).

The absorption spectrum of **2.6** has a similar maximum absorption as compared to **2.2**, while compounds **2.7** and **2.8** show a 30% reduction in absorption (Figure 2.13). The fluorescence properties of **2.2**, **2.6**, **2.7** and **2.8** in MeOH and buffer are summarized in Table 2.1. As shown in Figures 2.14 and 2.15, compound **2.6** has only a 5 nm Stoke's shift change as compared to that of **2.2**.

Compounds **2.7** and **2.8** have small wavelength shifts in their fluorescence spectra in comparison to **2.2**. Compound **2.7** contains an extra double bond, which extends the conjugation leading to a slight red shift (5 nm in excitation spectra and 15 nm in emission spectra). Compound **2.8** has somewhat less rigid aliphatic rings and shows a blue shift (25 nm in excitation spectra and 10 nm in emission spectra) compared to **2.2**.

The relative fluorescence quantum yields (ϕ) of **2.6**, **2.7** and **2.8** were calculated by using TR-SE **2.2** as the reference standard (Table 2.1). A reduction of 30 % in quantum yield is observed for compound **2.6** and a reduction of 17 % in quantum yield is observed for the compound **2.7**. However, compound **2.8** has 10 % enhancement in quantum yield as compare to TR-SE **2.2**.

TR-SE, (**2.2**) in both MeOH and 90 % PBS:DMSO solvents has similar absorbance and fluorescence intensities. A higher absorbance/fluorescence intensity is observed for **2.6**, **2.7** and **2.8** in organic solvent systems, compared to PBS/DMSO. This is attributed to the aggregation and π - π stacking effects that are mitigated in **2.2** due to the sulfonate group.

Figure 2.13 Absorption spectra of **2.2**, **2.6**, **2.7** and **2.8**. Probe concentration: 1.25 μM . Solvent: MeOH

Table 2.1 Comparison of the fluorescence properties of compounds **2.2**, **2.6**, **2.7** and **2.8**

Compound	MeOH	PBS:DMSO 9:1	Relative Quantum yield
	$\lambda_{\text{ex}}/\lambda_{\text{em}}$ (nm)	$\lambda_{\text{ex}}/\lambda_{\text{em}}$ (nm)	(ϕ)
2.2	580/600	590/610	1
2.6	575/600	580/600	0.71
2.7	590/615	590/620	0.83
2.8	560/590	565/590	1.1

Figure 2.14 Normalized fluorescence excitation spectra of **2.2**, **2.6**, **2.7** and **2.8**. Probe concentration: 1.25 μM . Solvent: MeOH

Figure 2.15 Normalized fluorescence emission spectra of **2.2**, **2.6**, **2.7** and **2.8**. Probe concentration: 1.25 μM . Solvent: MeOH

Figure 2.16 Absorption spectra of **2.2**, **2.6**, **2.7** and **2.8**. Probe concentration: 1.25 μ M. Solvent: PBS:DMSO 9:1

Figure 2.17 Normalized fluorescence excitation spectra of **2.2**, **2.6**, **2.7** and **2.8**. Probe concentration: 1.25 μ M

Figure 2.18 Normalized fluorescence emission spectra of **2.2**, **2.6**, **2.7** and **2.8**. Probe concentration: 1.25 μ M. Solvent: PBS:DMSO 9:1

2.5 Experimental section

Material and Methods

General. All chemicals were used as received without further purification. ^1H -NMR, ^{13}C -NMR and were acquired on an ARX-400 Avance Bruker spectrometer. Chemical shifts (δ) are given in ppm relative to TMS. Mass spectra were obtained at the PSU Bioanalytical Mass Spectrometry Facility on a ThermoElectron LTQ-Orbitrap Discovery high resolution mass spectrometer coupled to an Accela HPLC system. Microwave synthetic procedures were performed in an InitiatorTM microwave synthesizer (Biotage). Simulations were performed on a Dell precisionTM 490 work station loaded with CentOS 6.6 64-bit operating system using the molecular dynamics routines within the SYBYL XTM 2.0 modeling suite (Certara, L. P.). Fluorescence measurements were

carried out on a Cary EclipseTM fluorescence spectrophotometer (Agilent Technologies). Absorption spectra were acquired with a Cary EclipseTM 50 Bio UV-Vis spectrophotometer.

Synthesis of compound 2.11. In a 20 mL microwave tube, 8-hydroxyjulolidine (380 mg, 2 mmol) and 4-bromobenzaldehyde (185 mg, 1 mmol) were dissolved in 7.5 mL of methanesulfonic acid. A magnetic stirring bar was introduced and the tube was sealed and irradiated in the microwave reactor keeping the temperature at 150 °C with stirring for 5 min. The mixture was allowed to cool to rt, and the tube opened. Tetrachloro-1,4-benzoquinone (369 mg, 1.5 mmol) was added to the solution, and stirred for 15 min. The dark blue mixture was neutralized to pH 7 with 10 M KOH. The solution was poured into H₂O and extracted with CH₂Cl₂:MeOH 95:5 (3 × 100 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and the solvent removed under vacuum. The mixture was separated to give a dark violet solid (250 mg, 47%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁵⁶

Synthesis of compound 2.12. Bromorhodamine 2.11 (200 mg, 0.378 mmol) was dissolved in a solvent mixture including toluene (2.7 mL), aqueous 2 M Na₂CO₃ (1.2 mL) and 4-(*N*-Boc-amino) phenylboronic acid (459 mg 1.938 mmol) in EtOH (1.2 mL). The mixture was deoxygenated under reduced pressure and flushed with Ar 3 times. Pd(PPh₃)₄ (48 mg, 11 mol%) was added, and the reaction mixture heated at 60°C overnight. The solution was poured into H₂O, and washed with 10% MeOH in CH₂Cl₂. The organic layers were washed with brine and dried over Na₂SO₄, filtered over a short plug of celite and the solvent removed under vacuum. The mixture was separated by flash

chromatography on SiO₂ using CH₂Cl₂:MeOH 9:1 as the eluent to give a dark violet solid (109 mg, 45%). ¹H NMR (CDCl₃): 1.48 (9H, s, CH₃), 1.92 (4H, m, CH₂), 2.05 (4H, m, CH₂), 2.65 (4H, t, *J* = 6.0 Hz, CH₂), 2.98 (4H, d, *J* = 6.3 Hz, CH₂), 3.47 (4H, t, *J* = 5.7 Hz, CH₂), 3.51 (4H, t, *J* = 5.6 Hz, CH₂), 6.83 (2H, s, CH), 6.95 (1H, s, NH), 7.29 (2H, s, *J* = 8.2 Hz, CH), 7.50 (2H, d, *J* = 8.6 Hz, CH), 7.56 (2H, d, *J* = 8.6 Hz, CH), 7.70 (2H, d, *J* = 8.2 Hz, CH). ¹³C NMR (CDCl₃): 19.9, 20.0, 20.8, 27.8, 28.5, 50.6, 51.1, 80.8, 105.5, 112.9, 119.1, 123.8, 126.8, 126.9, 127.7, 130.1, 131.1, 134.1, 138.9, 142.2, 151.2, 152.3, 153.0, 154.7. HRMS (ESI): *m/z* [M⁺] calculated for C₄₂H₄₄N₃O₃: 638.3377; observed: 638.3378.

Synthesis of compound 2.13. To a stirred solution of compound **2.12** (97 mg, 0.151 mmol) in CH₂Cl₂ (3 mL) kept at 0 °C, TFA (4.5 mL) was added dropwise. The reaction was stirred for 2 h at 0 °C, and neutralized with saturated aqueous NaHCO₃ to pH 7. The organic layers were washed with H₂O, then brine, dried over Na₂SO₄, and the solvent removed under vacuum. The mixture was separated by flash chromatography on SiO₂ using a gradient solvent CH₂Cl₂:MeOH 95:5 to 90:10 as the eluent to afford a dark violet solid (yield: 72.4 mg, 89%). ¹H NMR (CDCl₃): 1.99 (4H, m, CH₂), 2.12 (4H, m, CH₂), 2.72 (4H, t, *J* = 6.0 Hz, CH₂), 3.05 (4H, d, *J* = 6.3 Hz, CH₂), 3.53 (4H, t, *J* = 5.7 Hz, CH₂), 3.57 (4H, t, *J* = 5.7 Hz, CH₂), 6.82 (2H, d, *J* = 8.5 Hz, CH), 6.92 (2H, s, CH), 7.33 (2H, d, *J* = 8.3 Hz, CH), 7.74 (2H, d, *J* = 8.5 Hz, CH), 7.79 (2H, d, *J* = 8.3 Hz, CH). ¹³C NMR (CDCl₃): 19.9, 20.0, 20.8, 27.8, 50.6, 51.1, 105.6, 113.0, 115.7, 123.7, 126.4, 126.9, 128.1, 129.6, 130.1, 130.3, 142.8, 147.1, 151.2, 152.4, 155.0. HRMS (ESI): *m/z* [M⁺] calculated for C₃₇H₃₆N₃O: 538.2853; observed: 538.2855.

Synthesis of compound 2.6. To a stirred solution of compound **2.13** (18.1 mg, 0.0325 mmol) in anhydrous CH₂Cl₂ (8 mL) was added 1,1'-thiocarbonyldi-2(1*H*)-pyridone (15.6 mg, 0.0672 mmol). The resulting mixture was stirred at rt for 18 h under Ar. The mixture was poured into CH₂Cl₂, washed with H₂O, then brine, dried over Na₂SO₄, and the solvent removed under vacuum. The residue was purified by flash chromatography on SiO₂ using CH₂Cl₂:MeOH 95:5 as the eluent to give a dark violet solid (13.8 mg, 71%). ¹H NMR (CDCl₃): 1.98 (4H, m, CH₂), 2.11 (4H, m, CH₂), 2.72 (4H, t, *J* = 5.9 Hz, CH₂), 3.04 (1H, t, *J* = 6.3 Hz, CH₂), 3.53 (4H, dd, *J* = 8.3 Hz, *J* = 6.2 Hz, CH₂), 3.56 (4H, t, *J* = 5.6 Hz, CH₂), 6.85 (2H, s, CH), 7.35 (2H, d, *J* = 8.5 Hz, CH), 7.41 (2H, d, *J* = 8.3 Hz, CH), 7.70 (2H, d, *J* = 8.5 Hz, CH), 7.79 (2H, d, *J* = 8.3 Hz, CH). ¹³C NMR (CDCl₃): 19.8, 20.0, 20.8, 27.8, 50.6, 51.1, 105.6, 112.8, 123.9, 126.5, 126.6, 127.4, 128.4, 130.3, 131.2, 132.2, 134.9, 138.9, 141.1, 151.3, 152.3, 154.1. HRMS (ESI): *m/z* [M⁺] calculated for C₃₈H₃₄N₃OS: 580.2417; observed: 580.2419.

Synthesis of compound 2.15. Compound **2.15** was synthesized using a modified procedure reported previously.⁵⁹ Under Ar, ytterbium(III) triflate (353 mg, 0.568 mmol) was added to solution of *m*-anisidine (1 g, 8.12 mmol) in HPLC grade acetone (40 mL). The reaction mixture was stirred at rt for 24 h. Acetone was removed *in vacuo* and the residue was dissolved in EtOAc, washed with H₂O, brine and dried over Na₂SO₄ filtered and the solvent evaporated under vacuum. The mixture was then separated by flash column chromatography on SiO₂ using Hexane:EtOAc 8:1 as the eluent to afford a pale yellow oily product (1.32 g, 80%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁵⁹

Synthesis of compound 2.16. Compound **2.16** was synthesized using a modified procedure reported previously.⁵⁹ Under Ar, compound **2.15** (5.55 g, 27.3 mmol), Cs₂CO₃ (4.98 g, 15.29 mmol), and MeI (6.46 mL, 103.75 mmol) were added to anhydrous DMF (15 mL) and stirred at 90 °C for 3 h. DMF was removed *in vacuo* and the residue poured into H₂O and washed with EtOAc (3 × 200 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure and a colorless oily product (5.28 g, 89%) was obtained. ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁵⁹

Synthesis of compound 2.17. Compound **2.17** was synthesized using a modified procedure reported previously.⁵⁹ Under Ar, compound **2.16** (3.05 g, 14.04 mmol) was dissolved in glacial AcOH (8.19 mL). 48% aqueous HBr (10.05 mL, 88.84 mmol) was added and the mixture heated at reflux (118 °C) for 8 h. After cooling, the solution was neutralized to about pH 5-6 with 30% aq. NaOH. The aqueous phase was extracted with CH₂Cl₂ (3 × 150 mL) and the combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was evaporated under reduced pressure. The mixture was then separated by flash column chromatography on SiO₂ using Hexane:EtOAc 5:1 as the eluent to yield dark red oily product (1.54 g, 54%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁵⁹

Synthesis of compound 2.19. In a 5 mL microwave tube, compound **2.17** (85 mg, 0.737 mmol) and methyl 4-(4-formylphenyl)benzoate (50 mg, 0.208 mmol) were dissolved in 1 mL CH₂Cl₂. The solvent was purged using an N₂ stream. The mixture was heated in a microwave reactor at 150 °C for 10 min. The mixture was dissolved in

CH₂Cl₂:MeOH (95:5, 1 mL) and tetrachloro-1,4-benzoquinone (76.75 mg, 0.312 mmol) was added to the solution, and vortexed at 1000 rpm for 15 min. The solvent was purged using an N₂ stream. The mixture was separated via a short SiO₂ plug using DCM:MeOH 97:3 as the eluent to afford compound **2.19** as a purple solid (85.15 mg, 67%). ¹H NMR(CDCl₃) : 1.49 (12H, s), 1.80 (6H, s) 3.21 (6H, s), 3.97 (3H, s), 5.51(2H, s), 6.85 (2H, s), 6.96 (2H, s), 7.52 (2H, d, *J* = 8.4 Hz) ,7.81 (2H, d, *J* = 8.6 Hz), 7.91 (2H, d, *J* = 8.4 Hz), 8.18 (2H, d, *J* = 8.6 Hz). ¹³C NMR (CDCl₃): 18.5, 29.44, 29.82, 33.51, 52.43, 59.96, 96.20, 113.79, 122.00, 123.64, 125.59, 127.28, 127.76, 129.97, 130.23, 130.51, 132.08, 132.75, 141.88, 143.95, 153.46, 154.12, 158.45, 166.91. HRMS (ESI): *m/z* [M⁺] calculated for C₄₁H₄₁N₂O₃⁺: 609.3112; observed 609.3125.

Synthesis of compound 2.21. Compound **2.19** (36 mg, 0.059 mmol) was dissolved in MeOH:THF:H₂O (5:3:1, 0.9 mL) and LiOH (7.07 mg, 0.295 mmol) was added. The reaction was stirred at rt overnight. After the reaction was complete (TLC), the residue was dissolved in CH₂Cl₂:H₂O (1:1, 2 mL). 1 N HCl was slowly added until the mixture was at pH 5. The aqueous layer was extracted with CH₂Cl₂ (3 × 5 mL), and the combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was evaporated under reduced pressure to afford compound **2.21** as a purple solid (27.43 mg, 78%). ¹H NMR(CD₃OD) : 1.52 (12H, s), 1.83 (6H, s) 3.21 (6H, s), 5.69 (2H, s), 6.86 (2H, s), 7.09 (2H, s), 7.65 (2H, d, *J* = 8.3 Hz) ,7.91 (2H, d, *J* = 8.3 Hz), 8.05 (2H, d, *J* = 8.3 Hz), 8.16 (2H, d, *J* = 8.3 Hz). ¹³C NMR (CD₃OD): 18.26, 29.16, 33.44, 61.26, 96.49, 114.89, 123.14, 124.77, 126.63, 128.17, 128.75, 131.61, 133.38, 134.13, 143.18, 145.14,

154.82, 156.00, 159.86. HRMS (ESI): m/z [M^+] calculated for $C_{40}H_{39}N_2O_3^+$: 595.2955; observed 595.2962.

Synthesis of compound 2.7. Compound **2.21** (20 mg, 0.033 mmol) was dissolved in 0.2 mL of anhydrous THF. EDAC (7.72 mg, 0.04 mmol) was added in one portion followed by *N*-Hydroxy succinimide (NHS) (4.64 mg, 0.04 mmol). The reaction was stirred at rt for 24 h. Another 10 equiv of EDAC (64.32 mg, 0.336 mmol) were added and the reaction stirred at rt overnight. The reaction mixture was poured into 10 mL of 50 mM pH 6 phosphate buffer and extracted with CH_2Cl_2 (3×15 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 , and the solvent evaporated under reduced pressure. The mixture was separated via a short SiO_2 plug using CH_2Cl_2 :MeCN 1:1, followed by gradient elution with CH_2Cl_2 :MeOH 98:2 to 95:5 to afford the target compound **2.7** as a purple solid (19.55 mg, 84%). 1H NMR($CDCl_3$) : 1.50 (12H, s), 1.81(6H, s), 1.95(4H, s), 3.23 (6H, s), 5.52 (2H, s), 6.86 (2H, s), 6.95 (2H, s), 8.28 (2H, d, $J = 8.4$ Hz) , 7.93 (2H, d, $J = 8.2$ Hz), 7.94 (2H, d, $J = 8.6$ Hz), 8.27 (2H, d, $J = 8.3$ Hz), 8.29 (2H, d, $J = 8.6$ Hz). ^{13}C NMR ($CDCl_3$): 18.54, 25.87, 29.46, 33.62, 60.00, 96.25, 113.79, 121.92, 123.70, 124.86, 125.57, 127.71, 127.90, 130.34, 131.50, 132.80, 141.28, 145.95, 153.48, 158.45, 161.72, 169.39. HRMS (ESI): m/z [M^+] calculated for $C_{44}H_{42}N_3O_5^+$: 692.3119; observed 692.3129.

Synthesis of compound 2.29. Under Ar, 2-bromo-4-methoxybenzaldehyde (1g, 4.65 mmol) was added to a solution of anhydrous THF (2 mL) and MeOH (2 mL) at rt. $NaBH_4$ (88mg, 2.33 mmol) was added in portions over 5 min. The reaction mixture was stirred at rt for 1.5 h and the solvent removed *in vacuo*. The residue was dissolved in

Et₂O and partitioned using Et₂O (10 mL), H₂O (10 mL) and 2M HCl (1 mL). The organic layer was washed with water twice, dried over Na₂SO₄ and concentrated *in vacuo* to afford **2.29** as a colorless oil (1g, 100%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁶²

Synthesis of compound 2.25. Under Ar, compound **2.29** (900 mg, 4.15 mmol) was dissolved in anhydrous Et₂O (13.5 mL). The solution was cooled using an ice bath and PBr₃ (780 mmL, 8.29 mmol) was added. The reaction was allowed to warm to rt and stirred overnight. The resulting orange solution was very carefully poured into vigorously stirred ice H₂O (20 mL) (CAUTION: HIGHLY EXOTHERMIC). Phases were separated, the combined organic layers were washed with saturated NaHCO₃ (10 mL) and dried over Na₂SO₄. The solvent was removed *in vacuo* to afford compound **2.25** as a white solid (1.1 g, 95%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁶²

Synthesis of compound 2.24. Compound **2.25** (1.04 g, 3.71 mmol) was added to a solution of KCN (483 mg, 7.42 mmol) in 20 mL EtOH. The reaction mixture was heated at reflux for 8 h. The solvent was removed *in vacuo* and the residue poured into 20 mL H₂O and extracted with EtOAc (3 × 30 mL). The organic layers were combined, washed with brine (20 mL), dried over Na₂SO₄ and concentrated *in vacuo* to afford compound **2.24** as a white solid (696 mg, 83%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁶³

Synthesis of compound 2.30. 40 wt. % methyl amine solution (6.61 mL, 76.42 mmol) was added to cyclohexene oxide (5.15 mL, 50.95 mmol) dropwise at 0 °C over 1 h.

The solution was allowed to warm to rt, stirred overnight and refluxed at 100 °C for 3 h. After reaction completion (TLC) the solution was cooled to 0 °C and 30% aq. NaOH was added to attain a pH > 12. The reaction mixture was extracted with Et₂O (3 × 200 mL) and dried over Na₂SO₄ and concentrated *in vacuo* to afford compound **2.26** as a colorless oil (6.58 g, 100%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁶⁴

Synthesis of compound 2.39. Compound **2.39** was synthesized using a modified procedure described previously by Acker *et al.*⁶⁵ Under Ar, 2-amino-4-methoxybenzoic acid (3 g, 17.95 mmol) was dissolved in 18 mL of anhydrous THF. Triphosgene (2.05 g, 6.82 mmol) was weighed in a glove box and dissolved in 6 mL anhydrous THF. The triphosgene solution was withdrawn by syringe and added dropwise to the benzoic acid solution over 1 h. The reaction mixture was heated at reflux (76 °C) for 2 h. The solvent was removed under reduced pressure, and the residue poured into 30 mL of cold H₂O. A white precipitate obtained was obtained by vacuum filtration, washed first with cold H₂O then with chilled CH₂Cl₂ (12.8 g, 95%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁶⁶

Synthesis of compound 2.35. Under Ar, isatoic anhydride (3 g, 15.53 mmol), Cs₂CO₃ (2.83 g, 8.7 mmol) and MeI (3.67 mL, 59.02 mmol) were added to anhydrous DMF (11 mL) and stirred at 90 °C for 3 h. DMF was removed *in vacuo*, and the residue poured into 30 mL of cold H₂O. The white precipitate formed was collected by vacuum filtration and washed with cold H₂O (2.98 g, 93%). ¹H NMR, ¹³C NMR and MS data are in agreement with the literature.⁶⁶

Synthesis of compound 2.43. *m*-anisidine (6g, 48.72 mmol) was dissolved in 180 mL anhydrous C₂H₂Cl₂ (DCE) followed by consecutive addition of ethyl 2-cyclohexanonecarboxylate (9.35 mL, 58.46 mmol), NaBH(OAc)₃ (15.49 g, 73.08 mmol) and AcOH (2.79 mL, 48.72 mmol). The reaction was stirred at rt overnight and monitored by TLC. After the reaction was complete, 180 mL of saturated NaHCO₃ was poured into the mixture followed by stirring for 30 min. The reaction mixture was extracted with CH₂Cl₂ (3 × 150 mL) and the combined organic layers were dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by flash column chromatography on SiO₂ using Hexane:EtOAc 15:1 as the eluent to afford compound **2.43** as a colorless oil (9.3 g, 69%). ¹H NMR(CDCl₃) : 1.23(3H, t, *J* = 7.1 Hz), 1.42-1.57 (3H, m) 1.64-1.75 (3H, m), 1.88-1.95 (1H, m), 1.97-2.07(1H, m), 2.84-2.88 (1H, m), 3.75-3.77 (1H, m), 3.79 (3H, s) ,4.07-4.17 (2H, m), 4.4 (1H, s), 6.20 (1H, t), 6.24-6.28 (2H, m), 7.08 (1H, t , *J* = 8.1 Hz). ¹³C NMR (CDCl₃): 14.30, 23.03, 23.34, 26.08, 29.08, 44.79, 51.62, 55.20, 60.43, 99.67, 102.52, 106.85, 130.09, 148.59, 160.97, 174.09. HRMS (ESI): *m/z* [M + H⁺] calculated for C₁₆H₂₄NO₃: 278.1751; observed 278.1743.

Synthesis of compound 2.44. Under Ar, compound **2.43** (6 g, 21.63 mmol) was dissolved in 16 mL of anhydrous DMF followed by addition of Cs₂CO₃ (3.95 g, 12.11 mmol) and MeI (5.12 mL, 82.2 mmol). The reaction mixture was heated at 90 °C and vigorously stirred for 3 h. After the reaction was complete, DMF was removed *in vacuo* and the residue poured into H₂O (100 mL) and washed with EtOAc (3 × 150 mL). The combined organic layers were dried over Na₂SO₄ and the solvent was removed under

reduced pressure to obtain a light yellow oil (5.04 g, 80%). ^1H NMR(CDCl_3) : 1.20 (3H, t, $J = 7.1$ Hz), 1.35-1.45 (1H, m) 1.53-1.55 (1H, m), 1.64-1.68 (3H, m), 1.93-2.01(2H, m), 2.39 (1H, q of d, $J = 12.3, 3.7$ Hz), 2.82 (3H, s), 3.08 (1H, m) ,3.75 (1H, d of t, $J = 12.0, 4.0$ Hz), 3.78 (3H, s), 4.00-4.12 (2H, m), 6.27 (1H, m), 6.34 (1H, d, $J = 8.3$ Hz), 7.15 (1H, t, $J = 8.2$ Hz). ^{13}C NMR (CDCl_3): 14.28, 21.45, 26.69, 26.95, 28.83, 32.45, 42.09, 55.27, 59.13, 60.20, 98.92, 100.67, 105.32, 129.95, 150.86, 160.97, 174.55. HRMS (ESI): m/z $[\text{M} + \text{H}^+]$ calculated for $\text{C}_{17}\text{H}_{25}\text{NO}_3$: 292.1907; observed 292.1894.

Synthesis of compound 2.40. A mixture of compound **2.44** (5.03 g, 17.26 mmol) and KOH (2.42 g, 43.14 mmol) in 15 mL MeOH were stirred at rt for 1h. An additional 5 equiv of KOH (4.84 g) were added and stirring was continued overnight. After the reaction was complete, MeOH was removed under vacuum. The residue was poured into CH_2Cl_2 and diluted with H_2O . The solution was acidified to pH 3 via slow addition of 1 N HCl. The reaction mixture was extracted with CH_2Cl_2 (3×150 mL) and the combined organic layers were dried with Na_2SO_4 . The solvent was removed *in vacuo* to afford a brown oil (crude yield: 4.5 g, 99%). ^1H NMR(CDCl_3) : 1.34-1.43 (2H, m), 1.34-1.56 (2H, m) 1.74-1.82 (4H, m), 2.31-2.35 (1H, m), 2.58(1H, t of d, $J = 11.6, 3.8$ Hz), 2.77 (3H, s), 3.58 (1H, t of d, $J = 11.4, 3.6$ Hz), 3.80 (3H, s), 6.44 (1H, d of d of d, $J = 8.2, 2.3, 0.6$ Hz), 6.54 (1H, t, $J = 2.3$ Hz), 6.60 (1H, d of d, $J = 5.3, 4.8$ Hz), 7.15 (1H, t, $J = 8.2$ Hz). ^{13}C NMR (CDCl_3): 25.22, 25.57, 26.76, 29.43, 31.86, 46.12, 55.39, 63.07, 103.97, 105.29, 110.12, 129.86, 151.29, 160.84, 177.78. HRMS (ESI): m/z $[\text{M} + \text{H}^+]$ calculated for $\text{C}_{15}\text{H}_{22}\text{NO}_3$: 264.1594; observed 264.1582.

Synthesis of compound 2.34. A mixture of compound **2.40** (0.5 g, 1.9 mmol) and polyphosphoric acid (6.3 g) was heated to 120 °C for 20 min. The reaction was cooled to rt and the solution neutralized to pH 7-8 with 15% aq. NaOH. The reaction mixture was extracted with EtOAc and the combined organic layers were dried over Na₂SO₄ and the solvent removed *in vacuo*. The residue was purified by column chromatography on SiO₂ using Hexane:EtOAc 8:1 as the eluent to compound **2.34** as a yellow solid. (75.58 mg, 16%). ¹H NMR(CDCl₃): 1.15-1.34 (3H, m), 1.42-1.51 (1H, m), 1.82-1.85 (1H, m), 1.89-1.91(1H, m), 2.22-2.29 (1H, m), 2.34-2.38 (1H, m), 2.42-2.47 (1H, m), 2.90 (3H, s), 3.06 (1H, d of d of d, *J* = 13.1, 11.3, 4.1 Hz), 3.84 (3H, s), 6.25 (1H, d, *J* = 2.2 Hz), 6.36 (1H, d of d, *J* = 8.7, 2.3 Hz), 7.89 (1H, d, *J* = 8.7 Hz). ¹³C NMR (CDCl₃): 24.76, 24.78, 24.87, 31.62, 32.79, 50.36, 55.43, 62.12, 97.92, 104.37, 114.69, 130.34, 154.85, 165.49, 194.33. HRMS (ESI): *m/z* [M + H⁺] calculated for C₁₅H₂₁NO₃: 246.1489; observed 246.1482

Synthesis of compound 2.33. Under Ar, to a solution of compound **2.34** (1 g, 4.08 mmol) in 12.5 mL of anhydrous Et₂O was added LiAlH₄ (464 mg, 12.23 mmol) portion-wise slowly. Once evolution of H₂ ceased, 12.5 mL dry toluene was added and the reaction heated at reflux (120 °C) for 2h. The mixture was cooled to 0 °C and followed by dropwise consecutive additions of 0.5 mL of H₂O, 0.5 mL of 15% NaOH and 1.5 mL of H₂O. The resultant precipitate was removed by vacuum filtration, washed with 60 mL CH₂Cl₂. The filtrate was concentrated *in vacuo* to afford compound **2.33** as a light yellow solid (929 mg, 99%). ¹H NMR (CDCl₃): 1.07-1.21 (2H, m), 1.24-1.41 (2H, m), 1.51-1.61 (1H, m), 1.71-1.75 (1H, m), 1.83-1.88 (2H, m), 2.26-2.30 (1H, m), 2.37-2.45 (1H, m), 2.37-2.45 (1H, m), 2.52 (1H, d of d, *J* = 15.1, 4.2 Hz), 2.68 (1H, t of d, *J* =

10.6, 3.6 Hz), 2.9 (3H, s), 3.77 (3H, s), 6.17 (1H, d of d, $J = 8.1, 2.4$ Hz), 6.22 (1H, d, $J = 2.4$ Hz), 6.81 (1H, d, $J = 8.0$ Hz). ^{13}C NMR (CDCl_3): 25.30, 25.84, 32.44, 33.03, 34.84, 35.99, 39.28, 55.34, 63.47, 99.44, 100.73, 116.63, 128.59, 148.47, 159.30. HRMS (ESI): m/z $[\text{M} + \text{H}^+]$ calculated for $\text{C}_{15}\text{H}_{22}\text{NO}$: 232.1696; observed 232.1684.

Synthesis of compound 2.32. Under Ar, compound **2.33** (1 g, 4.32 mmol) was dissolved in glacial AcOH (2.5 mL), 48% aq. HBr (3.03 mL, 26.8 mmol) was added and the mixture heated at reflux (118 °C) overnight. After cooling, the solution was neutralized to pH 5-6 with 30% aq. NaOH. The aqueous phase was extracted with CH_2Cl_2 (3×100 mL) and the combined organic layers were washed with brine and dry over Na_2SO_4 . The solvent was removed under reduced pressure to afford compound **2.32** as a brown solid (938 mg, 100%). ^1H NMR(CDCl_3) : 1.06-1.20 (2H, m), 1.23-1.41 (2H, m), 1.50-1.60 (1H, m), 1.71-1.74 (1H, m), 1.83-1.87 (2H, m), 2.25-2.29 (1H, m), 2.36-2.42 (1H, m), 2.50 (1H, d of d, $J = 15.1, 4.2$ Hz), 2.68 (1H, t of d, $J = 10.6, 3.6$ Hz), 2.87 (3H, s), 6.06 (1H, d of d, $J = 7.9, 2.4$ Hz), 6.14 (1H, d, $J = 2.3$ Hz), 6.74 (1H, d, $J = 7.8$ Hz). ^{13}C NMR (CDCl_3): 25.30, 25.83, 32.40, 33.02, 34.83, 35.87, 39.27, 63.38, 99.83, 102.71, 116.35, 128.83, 148.64, 154.99. HRMS (ESI): m/z $[\text{M} + \text{H}^+]$ calculated for $\text{C}_{14}\text{H}_{20}\text{NO}$: 218.1539; observed 218.1522.

Synthesis of compound 2.45. In a 2 mL microwave tube, compound **2.32** (108 mg, 0.499 mmol) and methyl 4-(4-formylphenyl)benzoate (60 mg, 0.25 mmol) were dissolved in 1 mL CH_2Cl_2 . The solvent was purged using an N_2 stream. The reaction mixture was heated in microwave reactor at 150 °C for 10 min. The mixture was dissolved in CH_2Cl_2 :MeOH (95:5, 0.5 mL) followed by addition of tetrachloro-1,4-

benzoquinone (92.1 mg, 0.375 mmol) and vortexed at 1000 rpm for 15 min. The solvent was removed using an N₂ stream. The mixture was separated via a short SiO₂ plug using CH₂Cl₂:MeCN 1:1, followed by CH₂Cl₂:MeOH 97:3 as the eluent to give a dark purple solid (67.3 mg, 42%). ¹H NMR(DMSO) : 1.11-1.47 (12H, m), 1.66-1.67 (2H, m), 1.77-1.85 (4H, m), 2.34-2.47 (4H, m), 2.66 (2H, d, *J* = 14.2 Hz), 3.21 (6H, s), 3.91(3H, s), 6.93 (2H, s), 6.99 (2H, s), 7.58-7.62 (2H, m), 7.99 (2H, d of d, *J* = 8.6, 2.1 Hz), 8.05 (2H, d of d, *J* = 8.5, 2.5 Hz), 8.11 (2H, d of d, *J* = 8.5, 1.1 Hz). ¹³C NMR (DMSO): 24.70, 24.77, 30.67, 31.36, 33.47, 35.60, 38.16, 52.27, 63.81, 96.28, 112.75, 126.50, 127.17, 127.35, 129.05, 129.97, 140.07, 143.49, 154.90, 156.48, 156.51, 165.99. HRMS (ESI): *m/z* [M⁺] calculated for C₄₃H₄₅N₂O₃⁺: 637.3425; observed 637.3381.

Synthesis of compound 2.46. Compound **2.45** (67 mg, 0.105 mmol) was dissolved in MeOH:THF:H₂O (5:3:1, 2.7 mL) and LiOH (12.58 mg, 0.525 mmol) was added. The reaction was stirred at rt overnight. After the reaction was complete, the residue was dissolved in CH₂Cl₂:H₂O (1:1, 2 mL), and 1 N HCl was slowly added to reach pH 5. The aqueous layer was extracted with CH₂Cl₂ (3 × 5 mL), and the combined organic layers were dried over Na₂SO₄. The solvent was removed *in vacuo* to furnish a purple solid (59.42 mg, 91%). ¹H NMR(CD₃OD) : 1.14-1.48 (12H, m), 1.66-1.69 (3H, m), 1.80-1.86 (3H, m), 2.34-2.48 (4H, m), 2.67 (2H, d, *J* = 13.6 Hz), 3.21 (6H, s), 6.9 (2H, s), 7.0 (2H, s), 7.6 (2H, d, *J* = 7.6 Hz), 7.96 (2H, d, *J* = 8.3 Hz), 8.05 (2H, d, *J* = 8.2 Hz), 8.10 (2H, d, *J* = 8.4 Hz). ¹³C NMR (CD₃OD): 24.71, 24.77, 30.68, 31.36, 33.48, 35.61, 38.17, 63.81, 96.27, 112.79, 126.52, 127.00, 127.31, 130.11, 131.86, 140.32, 143.00,

154.30, 154.92, 156.53, 167.09. HRMS (ESI): m/z $[M^+]$ calculated for $C_{42}H_{43}N_2O_3^+$: 623.3268; observed 623.3287.

Synthesis of compound 2.8. Compound **2.46** (8 mg, 0.013 mmol) was dissolved in 0.2 mL of anhydrous THF. EDAC (3.69 mg, 0.019 mmol) was added in one portion followed by the addition of NHS (1.77 mg, 0.015 mmol). The reaction was stirred at rt for 4 h. Another 5 equiv EDAC (12.3 mg, 0.063 mmol) were added and the reaction stirred at rt overnight. The reaction mixture was poured into 5 mL of 50 mM pH6 phosphate buffer, and extracted with CH_2Cl_2 (3×5 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 and the solvent evaporated *in vacuo*. The mixture was separated via a short SiO_2 plug using CH_2Cl_2 :MeCN 1:1 then DCM:MeOH 96:4 to afford the target compound **2.8** as a purple solid (7.68 mg, 83%). 1H NMR($CDCl_3$): 1.13-1.32 (8H, m), 1.36-1.42 (2H, m), 1.47-1.57(2H, m), 1.74 (2H, d, $J = 12.3$ Hz), 1.84 (2H, d, $J = 12.3$ Hz), 1.92 (2H, d, $J = 13.1$ Hz), 2.42-2.49 (4H, m), 2.60 (2H, d of d, $J = 15.2, 2.6$ Hz), 2.93 (4H, s), 3.12-3.18 (2H, m), 3.24 (6H, s), 6.82 (2H, s), 6.94 (2H, s), 7.49 (2H, d, $J = 8.2$ Hz), 7.84 (2H, d, $J = 8.5$ Hz), 7.88 (2H, d, $J = 8.3$ Hz), 8.26 (2H, d, $J = 8.5$ Hz). ^{13}C NMR ($CDCl_3$): 25.16, 25.25, 25.84, 29.76, 31.51, 32.04, 34.63, 36.20, 38.85, 64.80, 96.96, 113.59, 124.70, 126.83, 126.85, 126.91, 127.66, 127.87, 127.91, 127.95, 130.16, 130.26, 130.36, 131.46, 132.68, 141.10, 146.13, 154.62, 155.56, 157.24, 157.26, 161.70, 169.39. HRMS (ESI): m/z $[M^+]$ calculated for $C_{46}H_{46}N_3O_5^+$: 720.3426; observed 720.3432.

2.6 Conclusion

Molecular simulations guided the design of geometrically rigid fluorophores. A series of well-defined rhodamine analogs (**2.6**, **2.7** and **2.8**) have thus been synthesized to serve as the optical components of cationic drug-gentamicin conjugates. Inflexible Texas Red, **2.6**, was synthesized in four steps in 13% overall yield. A direct condensation of hydroxyl-quinoline and methyl 4-(4-formylphenyl)benzoate afforded the precursor to target **2.7**. Several attempts were evaluated to prepare the key intermediate to rhodamine **2.8**. An alternative approach including reductive amination and intramolecular Friedel-Crafts acylation was successful. The overall yield for **2.7** (6 steps) and **2.8** (9 steps) are 17% and 3%, respectively. Rhodamine derivatives, **2.6**, **2.7** and **2.8** in DPS/DMSO exhibited signs of aggregation, but in MeOH exhibited overall similar spectral properties compared to **2.2** has sulfonic groups improve solubility.

2.7 Future Work

- Continued systematic changes to fluorophore dimensions while keeping the rigid linker.
- Synthesis of fluorophores with semi-flexible (glycol) and flexible (alkyl) linker.

A series of gentamicin-fluorophore conjugates containing biaryl (inflexible), glycol (semiflexible) or alkyl (flexible) linkers will enable library generation and ensuing structure-activity relationship (SAR) studies to investigate if changing the fluorophore itself or linkers can help preserve fluorescence properties in cellular studies and complement the rigid analogs in defining channel properties.

CHAPTER 3 THE UTILITY OF RIGID FLUOROPHORE-GENTAMICIN CONJUGATES IN ZEBRAFISH AND KIDNEY CELL TRAFFICKING STUDIES

3.1 Introduction

AGs are essential for treating life-threatening bacterial sepsis, yet induce acute nephrotoxicity and permanent deafness. In order to have a better understanding of how AGs enter ear hair cells and kidney cells, GTTR **2.1** has been mainly used to study the mechanism of drug uptake. Recently, a candidate aminoglycoside transporter (sodium-glucose transporter-2; SGLT2) was identified that might be associated with kidney cytotoxicity.⁷² Molecular simulations (Figure 2.4) show that GTTR has a flexible linker that promotes conjugate folding thereby reducing its cross sectional diameter to pass through non-selective cation channels. A series of rigid and extended rhodamine derivatives (**2.6**, **2.7** and **2.8**) have been used to conjugate to gentamicin (**2.3** and **2.4**; **2.5** is in progress). The conjugates were prepared at OHSU by Meiyang Jiang in Prof. Steyger's group (Figure 3.1). These new analogs can serve as molecular rulers to determine the maximum dilated MET channel or transporter pore size, to better inform the prevention of cochlear hair cell uptake to preserve lifelong auditory function.

3.2 Synthesis of gentamin conjugates

Conjugates (**2.1**, **2.3** and **2.4**) were prepared using similar reaction condition as shown in Figure 3.1. Conjugation of the activated fluorophore (**2.2**, **2.6** and **2.7**) to gentamicin was carried out at pH 10 in aqueous media at rt (using a molar ratio of fluorophore:gentamicin 1:100 in order to ensure that only one molecule of the

fluorophore is conjugated to one molecule of gentamicin) with 60%, 25% and 10% yield, respectively.

Figure 3.1 Fluorophores-gentamicin conjugates

3.3 Cell Imaging Studies

MDCT (Mouse Distal Convoluted Tubule Cell Line) cells and zebrafish were used to study cellular uptake with conjugates **2.3** and **2.4** to evaluate the maximum permeation/dilation diameter of aminoglycoside-permissive channels and aminoglycoside transporters in hair cells and kidney cells.

3.3.1 MDCT cell

MDCT cells were chosen as an *in vitro* model of strial cells due to their common ion regulatory functions. MDCT cells were incubated with 5 µg/ml of each conjugate or the free fluorophores. As shown in Figure 3.2, there is a strong bright cytoplasmic and intra-nuclear fluorescence of MDCT cells (A1). MDCT cellular uptake of gentamicin diminishes with the increase in the cross-sectional diameter of the fluorophore. (Fluorescence intensity: **2.1** > **2.3** > **2.4**). This result suggests that larger diameter fluorophores may potentially prevent kidney cell gentamicin uptake. There is no uptake of free fluorophore as shown in B1, B2 and B3.

Figure 3.2 Cellular uptake of MDCT cells.

MDCT cells were incubated with 5 µg/ml conjugates. **2.1** (A1), **2.3** (A2) and **2.4** (A3); free fluorophores **2.2** (B1), **2.6** (B2) and **2.7** (B3) in PBS for 30 s, then fixation with 4% paraformaldehyde containing 0.5% Triton X-100 for 30 min. Scale bar = 20 µm

3.3.2 Zebrafish

Zebrafish are used as an ideal model for drug-screening assays due to its small size, optical transparency and high proliferation.⁷³ Also, they possess mechanosensitive hair cells on the surface of their body on the lateral line (sensory) system, sharing structural and molecular similarities with mammalian inner ear hair cells. They are also sensitive to aminoglycosides antibiotics.⁷⁴ The *mariner* zebrafish mutants have defective myosin VIIa that is critical for mechanotransduction by hair cells, and display defects in balance and acoustic startle reflexes owing to peripheral defects in the auditory/vestibular system.⁷⁵

As shown in Figure 3.3, zebrafish were treated with 1 µg/ml conjugates or free fluorophores for 10 min before fixation. Zebrafish neuromasts treated with **2.3** and **2.4** had significantly reduced hair cell uptake of gentamicin as compared to neuromasts treated with **2.1** only (A1-C1). These results indicate that the molecular modification of fluorophores reduces conjugate permeation through the MET channel and could prevent hair cell cytotoxicity. Based on the cross-sectional diameter of **2.3** and **2.4**, we can assume that the dilated MET channel pore size is approximately between 1.44 nm and 1.56 nm. Hair cell uptake was reduced in *mariner* zebrafish neuromasts compare to wild-type zebrafish. The myosin VIIa mutant zebrafish *mariner* with defective mechanotransduction is protected against hair cell damage caused by gentamicin (A1-F1). There is no free fluorophore uptake by wild-type and *mariner* zebrafish (G1-L1).

Figure 3.3 Cellular uptake with 1 $\mu\text{g/ml}$ conjugates and free fluorophores by wild-type and mariner zebrafish.

Neuromast hair cells can be identified by phalloidin-labeled (green) cuticular plates. **2.1** uptake (red) by hair cells is preferentially localized within the cytoplasm. A1-A2: Neuromast hair cells of wild-type larva incubated with **2.1** for 10 min display robust fluorescence. B1-B2: Neuromast hair cells of wild-type larva incubated with **2.3** for 10 min display less fluorescence intensity than **2.1**. C1-C2: Neuromast hair cells of wild-type larva incubated with **2.4** for 10 min display almost no fluorescence. D1-F2: **2.1**, **2.3**, **2.4** uptake in the neuromast hair cells of mariner larva are much less than that in wild-type larva. G1-I2: Neuromast hair cells of wild-type larva treated with the same dose of unconjugated **2.2**, **2.6** or **2.7** for 10 min display negligible fluorescence. J1-L2: Neuromast hair cells of mariner larva treated with the same dose of unconjugated **2.2**, **2.6** or **2.7** for 10 min display negligible fluorescence.

3.4 Experimental Section

Synthesis of Gentamicin-Texas Red conjugate, 2.1. An excess of gentamicin (Sigma, MO, USA) in 0.1 M potassium carbonate (pH 10) was mixed with TR-SE **2.2** (Invitrogen, CA) to minimize the possibility of over-labeling individual gentamicin molecules with more than one TR molecule, and to preserve the polycationic nature of the conjugate. After conjugation, reversed phase chromatography, using C-18 columns (Grace Discovery Sciences, IL), was used to purify GTTR from unconjugated gentamicin, and potential contamination by unreacted TR. The purified GTTR conjugate was aliquoted, lyophilized, and stored desiccated in the dark at -20 °C until use.

Synthesis of 2.6-gentamicin conjugate, 2.3. An excess of gentamicin (Sigma, MO, USA) in 0.1 M potassium carbonate (pH 8) was mixed with **2.6** (gentamicin: **2.6** = 100:1). The conjugation mixture reacted at rt for 2 days. After conjugation, chromatography using alumina columns and acetonitrile was used to purify **2.3** from unconjugated gentamicin, and potential contamination by unreacted **2.6**. The purified **2.3** was aliquoted, lyophilized, and stored desiccated in the dark at -20 °C until use.

Synthesis of 2.7-gentamicin conjugate, 2.4. An excess of gentamicin (Sigma, MO, USA) in 0.1 M potassium carbonate (pH 9) was mixed with **2.7** (gentamicin: **2.7** = 100:1). The conjugation mixture was left to react at rt for 7 days. After conjugation, reverse phase chromatography, using C-18 columns (Grace Discovery Sciences, IL), was used to purify **2.4** from unconjugated gentamicin, and potential contamination by unreacted **2.7**. The purification procedure is the same as GTTR purification. The purified

2.4 conjugate was aliquoted, lyophilized, and stored desiccated in the dark at -20 °C until use.

Gentamicin uptake by MDCT cells. MDCT cells plated on 8-well chambered coverslips were washed with cell medium twice, incubated with 5 µg/ml conjugates or free fluorophores in PBS for 30 s at rt to preclude endocytosis, then washed with PBS three times to remove conjugate from extracellular media prior to fixation with 4% paraformaldehyde containing 0.5% Triton X-100 for 30 min. The cellular distribution of conjugate fluorescence was examined using a Bio-Rad 1024 ES scanning laser system. For each individual set of images to be compared, the same confocal settings were used, with two acquisition images per well, two wells per experimental condition, and each experiment performed at least three times to confirm the consistency of experimental data.

Gentamicin uptake by zebrafish. Zebrafish wild-type and *mariner* zebrafish larvae, 5 days after fertilization, were treated with conjugates or free fluorophores; (1µg/ml in standard E3 medium for 10 min prior to fixation in 4% formaldehyde for 1 h and 0.5% Triton X-100 for 30 min.) Larvae were then labeled with Alexa-488-conjugated phalloidin to confirm hair cell bundles by confocal microscopy.

3.5 Conclusion

Genetic inhibition of mechanotransduction reduces gentamicin-fluorophore conjugate uptake. Also, structural modifications of the fluorophore reduce or block gentamicin uptake in kidney and hair cells. The conjugates via their fixed diameters, when used as to measure the maximum dilated MET channel pore size, show that this

might be between 1.44 nm to 1.56 nm. However, this needs further validation, for instance, with a larger diameter fluorophore conjugate (**2.5**), which is currently in progress.

3.6 Future

- Synthesis of fluorophore-gentamicin conjugate **2.5**
- Use conjugate **2.5** to verify the dilated ion channel pore size and test if the structure of this fluorophore is effective in blocking cellular uptake.
- Isolate the gentamicin isomer mixture

Gentamicin C₁

Gentamicin C₂

Gentamicin C_{1a}

CHAPTER 4 SYNTHESIS OF A CISPLATIN-TEXAS RED CONJUGATE

4.1 Introduction

Cisplatin is one of the most powerful anticancer drugs used to treat a wide range of cancers. However, its unwanted side-effects such as ototoxicity and nephrotoxicity remain problematic at the dose required for clinical efficacy. There have been several studies to identify the biodistribution of cisplatin in cells and tissues using positron emission tomography, radiolabeled cisplatin and high-performance liquid chromatography (HPLC).⁷⁶⁻⁷⁹ Morphologically, these techniques have low anatomic resolution, and cannot provide the cellular distribution of cisplatin in heterogeneous cellular tissues, like the cochlea in the inner ear. In order to investigate the cellular uptake and intracellular distribution of cisplatin, the use of fluorogenic probes offers an alternative method to these techniques. A fluorescein-cisplatin conjugate has been reported to enter cells via endocytosis.⁸⁰ Recently, a rhodamine-cisplatin has been reported to enter sensory hair cell of the zebrafish neuromast via their apical membranes, potentially via the MET channel or calmodulin-dependent endocytosis.³⁵ Several fluorophore-cisplatin conjugates, including fluorescein, cyanine, coumarin and dinitrophenyl, have also been studied (Figure 4.1).⁸¹ Results reveal that the reactivity of the cisplatin conjugate towards a guanine base is determined to a large extent by the charge properties of the fluorophore: cationic > neutral > anionic.

Thus, it is proposed that the conjugation of anionic dyes such as fluorescein diminishes or neutralizes cisplatin's cationic properties and thus change its bioactivity, as observed for fluorescein-conjugated aminoglycosides.³⁶ In order to preserve the drug

cationic properties, it was envisioned that tagging cisplatin with a rhodamine type fluorophore would overcome these concerns, similar to that for Texas Red-tagged gentamicin.^{42,82}

Figure 4.1 Fluorophores have been conjugated with cisplatin and its structure

Therefore, a method was described here to conjugate a cationic commercially-available fluorophore, TR-SE **2.2** to cisplatin (**4.1**, Figure 4.1) and following systemic injection, will allow to determine localization of cisplatin uptake mechanism within cochlear. A fluorescein-cisplatin conjugate (**4.2**) was also synthesized and used as a control to study the fluorophore property influence on cellular uptake. A better understanding of the biodistribution of cisplatin, and uptake mechanisms, will facilitate

the design of new platinum-based pharmacotherapies to diminish or ameliorate the devastating side effects of cisplatin therapy.

Figure 4.2 Isomers of Cisplatin-Texas Red conjugate, **4.1** and fluorescein conjugate, **4.2**

4.2 Synthetic strategies of cisplatin conjugates

4.2.1 Synthesis of cisplatin-fluorescein conjugate, **4.2**

Platinum complex **4.5** was considered appropriate as a cisplatin analogue as it contains a short linker for conjugation and has biological properties similar to cisplatin. Complex **4.3** is synthesized in three steps as described previously by Benoist *et al.*⁸³ The Boc-protected ligand **4.3** possessing free amino groups can, upon chelation with Pt(II), afford complex **4.4** in 75% yield. The deprotected platinum complex **4.5** is obtained quantitatively by acid hydrolysis of **4.4**.⁸⁴ The overall yield for the platinum complex **4.5** is 53%.

Scheme 4.1 Synthesis of platinum complex **4.5**

The synthesis of control fluorescein-cisplatin conjugate (DDP-Fl) was carried out as shown in scheme 4.2. using a known protocol reported by Molenaar *et al.*⁸⁴ Commercially available fluorophore, 5(6)-carboxyfluorescein diacetate *N*-succinimidyl ester (**4.6**, CFDA-SE), is conjugated to deprotected platinum complex **4.5** in anhydrous DMF to afford **4.2** in 23% yield.

Scheme 4.2 Synthesis of DDP-Fl, **4.2**

The reversed-phase HPLC analysis of both CFDA-SE **4.6** and the conjugate **4.2** showed only one major peak, without separation. The purity of the conjugate was calculated as 92 %. (Figure 4.3 and 4.4)

Figure 4.3 HPLC trace of compound **4.6** (isomer mixture).
The injected volume: 5 μ L. Flow rate 0.2 mL/min; using a H₂O:MeCN gradient 70:30 to 95:5 in 25 min; wavelength detection 235 nm.

Figure 4.4 HPLC trace of compound **4.2**(isomer mixture).
The injected volume: 5 μ L. Flow rate 0.2 mL/min; using a H₂O:MeCN gradient 70:30 to 95:5 in 25 min; wavelength detection 235 nm.

4.2.2 Synthesis of cisplatin-Texas Red conjugate, **4.1**

The target DDP-TR **4.1** was synthesized as shown in scheme 4.3 in 48% overall yield. Conjugation was performed by reacting commercially available fluorophore, TR-SE **1.1**, with deprotected platinum complex **4.5** under basic conditions in 88% yield.

DDP-TR **4.1** is characterized by ^1H NMR, ^{13}C NMR, ^{195}Pt NMR and LC/MS. The ^{195}Pt NMR spectrum of conjugate **4.1** exhibits a chemical shift at -2265.40 ppm while the resonance of its parent Pt complex **4.5** is at -2367.05 ppm.

Scheme 4.3 Synthesis of DDP-TR, **4.1**

Reversed-phase HPLC analysis shows that the commercial TR-SE **2.2** is actually a mixture containing two isomers (**2.2a** and **2.2b**, Figure 4.5) in a 2:1 ratio (Figure 4.6). After conjugation of **2.2** to platinum complex **4.5**, as expected a more hydrophilic molecule was obtained and the isomer ratio was unchanged (Figure 4.7). The purity of conjugate **4.1** (also a 2:1 mixture of isomers) was calculated as 97% by reversed phase HPLC. Table 4.1 shows the retention time and composition of both isomeric mixtures. In addition, the HR ESI positive mode MS spectrum was used to confirm the identity of conjugate **4.1**, showing the typical isotope pattern of Pt for the parent ion.

Figure 4.5 Texas Red succinimidyl ester isomers

Figure 4.6 HPLC trace of compound **2.2** (isomer mixture).

The injected volume is 5 μ L. Flow rate 0.2 mL/min; using a H₂O:MeCN gradient 95:5 to 5:95 in 25 min; wavelength detection: 590 nm.

Figure 4.7 HPLC trace of compound **4.1** (isomer mixture).

The injected volume is 5 μ L. Flow rate 0.2 mL/min; using a H₂O:MeCN gradient 95:5 to 5:95 in 25 min; wavelength detection: 590 nm.

Table 4.1 Retention times and peak areas for each isomer.

	Retention Time		Composition %	
	Compound 4.1	Compound 2.2	Compound 4.1	Compound 2.2
Peak 1	16.39	19.00	66.88	66.85
Peak 2	17.92	20.98	33.12	33.15

4.3 Spectral properties

Spectroscopic characterization of the cisplatin-Texas Red conjugate 4.1

In order to determine the newly conjugate **4.1** has the similar spectral properties as the parent probe TR-SE (**2.2**), the absorbance and fluorescence spectra of 1.25 μ M solution of **4.1** and **2.2** were evaluated in MeOH.

Compound **4.1** revealed that the conjugate has similar maximum absorbance intensity as compared to the parent fluorophore, **2.2** (Figure 4.8). As shown in Figure 4.9, the fluorescence excitation maximum was slightly red-shifted by 5 nm in compound **4.1**, otherwise negligible changes in emission spectra were observed compared to **2.2**. Therefore, conjugation to cisplatin preserves the spectral properties of TR-SE, **2.2**.

Figure 4.8 Absorption spectra of 1.25 μM of **4.1** and **2.2** in MeOH.

Figure 4.9 Excitation/Emission fluorescence spectra of 1.25 μM of **4.1** and **2.2** in MeOH.

4.4 Cellular studies

In order to test the hypothesis that anionic fluorescein will diminish cisplatin's cationic properties and change its bioactivity, both DDP-Fl (**4.2**) and DDP-TR (**4.1**) were used in MDCK (Madin-Darby Canine Kidney) cells for this study. In addition, zebrafish neuromast hair cells were used to verify the cytotoxicity.

Cellular uptake by MDCK cells with DDP-FI (4.2) and DDP-TR (4.1)

Cells were incubated with 10 $\mu\text{g/ml}$ of DDP-FI or DDP-TR for 30 s at rt to preclude endocytosis, then fixed with formaldehyde plus Triton X-100 for 40 min and imaged with similar laser power settings. Cellular uptake of DDP-TR had stronger fluorescent intensity than cells treated with DDP-FI. This suggests that anionic property of fluorescein may potentially change the bioactivity of cisplatin and renders no cellular uptake. (Figure 4.10)

Figure 4.10 Comparison of DDP-FI (A) and DDP-TR (B) uptake by MDCK cells. MDCK cells were treated with 10 $\mu\text{g/ml}$ of conjugates for 30 s at 20°C to preclude endocytosis, fixed with formaldehyde plus Triton X-100 for 40 min. The scale bar is 10 microns.

DDP-TR toxicity in zebrafish neuromast hair cells

To verify that DDP-TR retains the cytotoxic properties of cisplatin, the relative toxicity of cisplatin and DDP-TR were compared using zebrafish neuromast hair cells. Larvae were treated with a dose range of cisplatin, DDP-TR, or unconjugated Texas Red for 4 h and allowed to recover for 3 h.

Alexa-488-conjugated phalloidin labeling of the hair bundle and cuticular plate determined the number of surviving hair cells. Hair cells can cleave their hair bundles

following drug exposure,⁸⁵ yet the loss of the hair bundle or cuticular plate is an ototoxic event. After treatment with DDP-TR (10-200 $\mu\text{g}/\text{mL}$) for 4 h, plus 3 h of recovery, the number of surviving hair cells decreased with increasing dose (Figure 4.11A-C, E). Treatment with unconjugated Texas Red revealed no fluorescence in hair cells suggesting that the forced uptake of Texas Red, via conjugation to cisplatin, was responsible for the enhanced toxicity of DDP-TR. (Figure 4.11D) To quantify and normalize this decrease, untreated controls provided a baseline to determine the ratio of surviving hair cells in zebrafish neuromasts. Both cisplatin and DDP-TR decreased hair cell numbers in a dose-dependent manner (Figure 4.11E).

Figure 4.11 Cytotoxicity in zebrafish neuromast hair cells with a range of dose.

(A-C) To verify the cytotoxicity of DDP-TR, **4.1** a zebrafish was treated with various concentrations of conjugate (50-200 $\mu\text{g}/\text{mL}$) for 4 h, plus 3 h of recovery. Upon increasing the dose of conjugate, the number of hair cells decreased. (D) Treatment with unconjugated Texas Red showed no fluorescence within neuromasts. (E) Quantifying the relative surviving hair cells of zebrafish with cisplatin and conjugate treatment: the conjugate appears less toxic than cisplatin.

4.5 Experimental section

Material and Methods

General. All chemicals were used as received without further purification. ^1H -NMR, ^{13}C -NMR and ^{195}Pt -NMR were acquired on an ARX-400 Avance Bruker spectrometer. Chemical shifts (δ) are given in ppm relative to TMS. For ^{195}Pt -NMR, K_2PtCl_4 was used as external standard. Mass spectra was conducted at PSU Bioanalytical Mass Spectrometry Facility on a ThermoElectron LTQ-Orbitrap Discovery high resolution mass spectrometer coupled to an Accela HPLC system. The reversed phase HPLC consists of a 1525 binary delivery system, and a 2996 Photodiode array detector (Waters). A SupelcoTM C-18 (25 cm $\times$ 2.1 mm, 5 μm) column was used for the separation. Fluorescence measurements were carried out on a Cary EclipseTM fluorescence spectrophotometer (Agilent Technologies), and absorption measurements were performed on a Cary EclipseTM 50 Bio UV-Vis spectrophotometer.

Synthesis of N_3 -(tert-Butoxycarbonyl)-1,2,3-propanetriamine, 4.3. Compound **4.3** was synthesized from 3-amino-1,2-propanediol in three steps as reported by Benoist *et al.* with an overall yield of 73%. NMR spectroscopic and MS data are in agreement with the literature.⁸³

Synthesis of N -(tert-Butoxycarbonyl)-1-aminomethyl-1,2 ethylenediamine) dichloroplatinum(II), 4.4. Compound **4.4** was synthesized using a modified procedure reported previously by Molenaar *et al.* Under Ar system, K_2PtCl_4 (1.1 g, 2.64 mmol) was dissolved in 50 mL of DI water. The Boc-protected diamine **4.3** (0.5 g, 2.64 mmol) was dissolved in 10 mL of DI water and added to the K_2PtCl_4 solution. The reaction mixture

was stirred at rt for 24 h, and a pale yellow solid was formed. The solid was filtered, washed with H₂O (5 × 50 mL), and dried under vacuum (yield: 0.9 g, 75%). NMR spectroscopic and MS data are in agreement with the literature.⁸⁴

Synthesis of (1-aminomethyl-1,2-ethylenediamine)dichloroplatinum(II) hydrochloride, 4.5. Compound **4.4** (0.518 g, 1.137 mmol) was suspended in 50 mL of 0.1M HCl, followed by the addition of 2.5 mL of 1.0 M HCl. The reaction mixture was heated at 50 °C for 24 h. More 1 M HCl (0.5 mL) was added and the reaction mixture was kept at 50 °C for another 24 h. The reaction was cooled down to rt and the aqueous solution was filtered through a 22 µm syringe filter to remove white precipitates. The filtrate was evaporated under vacuum to afford a yellow solid (441 mg, 99%). NMR spectroscopic and MS data are in agreement with the literature.⁸⁴

Synthesis of DDP-FI, 4.2. Compound **4.2** was synthesized using a procedure reported by Molenaar *et al* in 23% yield. NMR spectroscopic and MS data are in agreement with published values.⁸⁴

Synthesis of DDP-TR, 4.1. Platinum complex **4.5** (10.55 mg, 26.93 µmol) was dissolved in 1.2 mL of anhydrous DMF and sonicated for 10 min. Et₃N (10.24 µL, 73.44 µmol) was added in one portion and the mixture was sonicated for another 5 min, resulting in a clear pale yellow solution; if necessary, DI water was added in increments of 20 µL and sonicated until completely dissolved. TR-SE **2.2** (20 mg, 24.48 µmol; Invitrogen CA) was added, and the reaction mixture stirred at rt for 1 h, prior to evaporation under vacuum to afford a purple precipitate. The residue was centrifuged and washed with cold H₂O (2 × 10 mL) and Et₂O (3 × 10 mL) until the supernatant became

almost clear, and dried under vacuum to afford a purple solid (yield: 88%, 22.8 mg). HRMS (ESI): m/z $[M + H]^+$ calculated for $C_{41}H_{51}Cl_2N_6O_7PtS_2$: 1056.2282; observed 1056.2354. Moreover, the HPLC-MS analysis confirms that the first peak from the conjugate isomers of **4.1** appears at 17.67 min with m/z of 1056.2322 for $[M + H]^+$, and the second peak appears at 19.15 min with m/z of 1056.2260 for $[M + H]^+$.

HPLC Analysis

HPLC analysis of Compounds 4.1 and 2.2. The injected volume of **4.1** and **2.2** was 5 μ L. The mobile phase consisted of H_2O :MeCN with a gradient elution from 95:5 to 5:95 in 25 min, with a flow rate of 0.2 mL/min. The UV/Vis scan range was 200-700 nm. The detection wavelength was set at 590 nm.

HPLC analysis of Compounds 4.2 and 4.6. The injected volume of **4.2** and **4.6** was 5 μ L. The mobile phase consisted of H_2O :MeCN with a gradient elution from 70:30 to 95:5 in 25 min, with a flow rate of 0.2 mL/min. The detection wavelength was set at 235 nm.

Fluorescence Spectroscopic Evaluation

Fluorescence Spectra of Compounds 4.1 and 2.2. Stock solutions of **4.1** and **2.2** were prepared in MeOH. Fluorescence spectra were recorded at excitation/emission wavelengths of 585 nm/600 nm (compound **4.1**) and 580 nm/600 nm (compound **2.2**) with the bandwidths set at 5 nm.

Cellular studies

MDCK cells. MDCK cells were cultured in antibiotic and phenol red-free Dulbecco's minimal essential medium (MEM, Invitrogen, Ca) with 10% fetal bovine

serum at 37°C with 5% CO₂, 95% air. Cells were seeded into 8-well coverglass chambers (ISC BioExpress) at 3000 cells/well and grown for 5 days, when they had become subconfluent, cuboidal, and had time to develop tight junctions. Cells were washed three times with PBS (with 1.25 mM calcium) and treated with 10 µg/ml of DDP-Fl or DDP-TR for 30 s at 20°C to preclude endocytosis, fixed with formaldehyde plus Triton X-100 for 40 min and then imaged with approximately similar laser power settings.

Zebrafish. Wildtype zebrafish larvae, 5 days after fertilization, were treated with a dose range of DDP-TR or cisplatin (10 to 400 mg/ml in standard E3 medium) for 4 h and recovered for 3 h prior to fixation in 4% formaldehyde containing 0.5% Triton X-100. Larvae were then labeled Alexa-488-conjugated phalloidin to determine the number of surviving hair cell bundles.

4.6 Conclusion

Platinum complex **4.5** with a short linker for conjugation was synthesized in 5 steps with 53 % yield. DDP-TR, **4.1** was successfully synthesized using platinum complex **4.5** conjugated with commercially available TR-SE (**2.2**) with an unchanged isomer ratio in 97% purity. Spectroscopic evaluation showed that the conjugation of cisplatin preserved the spectral properties of Texas Red, **2.2**.

Cellular studies showed that the anionic properties of fluorescein neutralize positive charge of cisplatin and change its bioactivity: there is no cellular uptake of DDP-Fl by MDCK cell as comparison with DDP-TR, **4.1**. Cisplatin is a relatively small molecule, so conjugation could alter the kinetics of uptake as well as cytotoxicity. *In*

vitro studies showed that the new DDP-TR has similar but reduced cytotoxicity to hair cells as compared to unconjugated cisplatin, and in a dose-dependent manner.

4.7 Future Work

- Conjugation of cisplatin to the series of rhodamine analogs to serve the same purpose as gentamicin conjugates in determining ion channel and transporter properties.

CHAPTER 5 SYNTHESIS OF A TETRAAMINO PLATINUM-TEXAS RED CONJUGATE

5.1 Introduction

Carboplatin (Figure 5.1) is an analog of cisplatin and is widely used but for fewer types of cancers compared to cisplatin. These include ovarian, lung, and head and neck cancers.²⁵ Carboplatin is less toxic as compared to cisplatin due to replacing cisplatin's chloride leaving groups with a cyclobutane-1,1-dicarboxylato ligand.⁸⁶ This increases stability and inhibits exchange with aqua ligands leading to the more bioactive form that induces cytotoxicity in the cochlea and kidney.⁸⁷ Even though carboplatin is less ototoxic and nephrotoxic compared to cisplatin, the cytotoxicity and these unwanted side-effects still occurs and remains an issue for clinical efficacy.⁸⁸

Figure 5.1 Carboplatin

A common structural feature shared by cisplatin and carboplatin is the diamine groups. These drugs can induce cytotoxicity through molecular interactions via their amino groups. It is hypothesized that proteins specifically bind to cisplatin and carboplatin at the two amines, and that the protein-drug interactions could induce cell death associated with toxicity to the cochlea and kidney. The analogous amine platinum complex (**5.1**, Figure 5.2) has been previously synthesized and used to identify cisplatin-binding proteins relevant to cytotoxicity, but not specific to the cochlea and kidney.⁸⁹

Therefore, in order to identify the biodistribution of platinum binding proteins *in vivo* in heterogeneous cellular composition in kidney and cochlea, it is proposed to synthesize the tetra-amino platinum Texas Red conjugate as shown in Scheme 5.1.

5.2 Synthesis of a tetra-amino platinum complex and its Texas Red Conjugate

Figure 5.2 Amino platinum complex **5.1** and its proposed Texas Red conjugate **5.2**

Platinum complex **5.1** was chosen as an analog of cisplatin and carboplatin because it contains a free amine terminated short linker to allow conjugation to the fluorophore. It is expected that the two free amine groups will bind to proteins, which will allow one to determine if this structural feature is responsible for the lower cytotoxicity observed for carboplatin.

The corresponding platinum complex, **4.5** and platinum complex **5.1**, bearing a free amino group for further conjugation to other biomolecules, were synthesized as shown in scheme 5.1. Complex **5.1**, was synthesized in 52% overall yield following a

modified procedure by Hall *et al.*⁹⁰ The Pt complex **5.1** was obtained in 98% yield from **4.5**, via the formation of the di-aquo complex **5.3**, followed by ligand exchange with excess of NH_4OH . All synthesized platinum complexes were characterized by ^1H NMR, ^{13}C NMR, ^{195}Pt NMR and ESI/MS. The synthesis of conjugate **5.2** is currently underway, which will be performed by conjugation of **5.1** to TR-SE **2.2** under basic condition in anhydrous DMF or by ligand exchange following the same procedure as the one used to obtain compound **5.1**.

Scheme 5.1 Proposed synthetic scheme of **5.2**

5.3 Conclusion and future work

The tetra-amino platinum complex **5.1** has been synthesized and used to identify cisplatin-binding proteins. Effort is underway to synthesize a fluorescent tetra-amino platinum conjugate, **5.2**. It will be used to study the biodistribution *in vivo* of the tetra-amino platinum complex and cellular uptake as compared to the control conjugate of DDPTR **4.1**.

References

1. Sanders, W. E.; Pejovic, I.; Cacciatore, R.; Valdez, H.; Dunbar, F. P. *J. Infec. Dis.* **1971**, *124*, S33.
2. Cottagnoud, P.; Gerber, C. M.; Cottagnoud, M.; Tauber, M. G. *Antimicrob. Agents Chemother.* **2002**, *46*, 188.
3. Clancy, J. P.; Bebok, Z.; Ruiz, F.; King, C.; Jones, J.; Walker, L.; Greer, H.; Hong, J.; Wing, L.; Macaluso, M.; Lyrene, R.; Sorscher, E. J.; Bedwell, D. M. *Am. J. Respir. Crit. Care. Med.* **2001**, *163*, 1683.
4. Zaske, D. E.; Bootman, J. L.; Solem, L. B.; Strate, R. G. *Surgery* **1982**, *91*, 142.
5. Pillers, D. M.; Schleiss, M. R. *The Volta Review* **2005**, *105*, 205.
6. Kahlmeter, G.; Dahlager, J. I. *J. Antimicrob. Chemother.* **1984**, *13*, 9.
7. Mohr, P. E.; Feldman, J. J.; Dunbar, J. L.; McConkey-Robbins, A.; Niparko, J. K.; Rittenhouse, R. K.; Skinner, M. W. *Int. J. Technol. Assess. Health Care* **2000**, *16*, 1120.
8. Begg, E. J.; Barclay, M. L. *Br. J. Clin. Pharmacol.* **1995**, *39*, 597.
9. Kohanski, M. A.; Dwyer, D. J.; Collins, J. J. *Nat. Rev. Microbiol.* **2010**, *8*, 423.
10. Hashino, E.; Shero, M.; Salvi, R. J. *Brain Res.* **2000**, *887*, 90.
11. Sandoval, R.; Leiser, J.; Molitoris, B. A. *J. Am. Soc. Nephrol.* **1998**, *9*, 167.
12. Decorti, G.; Malusa, N.; Furlan, G.; Candussio, L.; Klugmann, B. F. *Life Sci. Res. Rep.* **1999**, *65*, 1115.
13. Marcotti, W.; van Netten, S. M.; Kros, C. J. *J. Physiol.* **2005**, *567*, 505.
14. Hashino, E.; Shero, M. *Brain Res.* **1995**, *704*, 135.
15. Wang, Q.; Kachelmeier, A.; Steyger, P. S. *Hear. Res.* **2010**, *268*, 250.
16. Rosenberg, B.; Van Camp, L.; Krigas, T. *Nature* **1965**, *205*, 698.
17. Roberts, D.; O'Dwyer, P.; Johnson, S. In *Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures*; Minev, B. R., Ed.; Springer Netherlands: 2011; Vol. 13, p 145.
18. Wong, E.; Giandomenico, C. M. *Chem. Rev.* **1999**, *99*, 2451.

19. Weiss, R. B.; Christian, M. C. *Drugs* **1993**, *46*, 360.
20. Einhorn, L. H. *Proc. Natl. Acad. Sci. U. S. A.* **2002**, *99*, 4592.
21. Knight, K. R.; Kraemer, D. F.; Neuwelt, E. A. *J. Clin. Oncol.* **2005**, *23*, 8588.
22. Knight, K. R.; Kraemer, D. F.; Winter, C.; Neuwelt, E. A. *J. Clin. Oncol.* **2007**, *25*, 1190.
23. Skinner, R.; Pearson, A. D.; English, M. W.; Price, L.; Wyllie, R. A.; Coulthard, M. G.; Craft, A. W. *Br. J. Cancer* **1998**, *77*, 1677.
24. Kostova, I. *Recent Patents Anticancer Drug Discov.* **2006**, *1*, 1.
25. Wang, D.; Lippard, S. J. *Nat. Rev. Drug Discov.* **2005**, *4*, 307.
26. Ozkok, A.; Edelstein, C. L. *BioMed Research International* **2014**, *2014*, 17.
27. Siddik, Z. H. *Oncogene* **2003**, *22*, 7265.
28. Kruidering, M.; van de Water, B.; de Heer, E.; Mulder, G. J.; nagelkerke, J. F. *J. Pharmacol. Exp. Ther.* **1997**, *280*, 638.
29. Baliga, R.; Zhang, Z.; Baliga, M.; Ueda, N.; Shah, S. V. *Kidney Int.* **1998**, *54*, 1562.
30. Burger, H.; Loos, W. J.; Eechoute, K.; Verweij, J.; Mathijssen, R. H. J.; Wiemer, E. A. C. *Drug Resist. Updat.* **2011**, *14*, 22.
31. Hall, M. D.; Okabe, M.; Shen, D.-W.; Liang, X.-J.; Gottesman, M. M. *Annu. Rev. Pharmacol. Toxicol.* **2008**, *48*, 495.
32. Spreckelmeyer, S.; Casini, A.; Orvig, C. *Molecules* **2014**, *19*, 15584.
33. Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstaedt, H.; Lanvers-Kaminsky, C.; Zehnhoff-Dinnesen, A. a.; Schinkel, A. H.; Koepsell, H.; Juergens, H.; Schlatter, E. *Am. J. Pathol.* **2010**, *176*, 1169.
34. More, S. S.; Akil, O.; Ianculescu, A. G.; Geier, E. G.; Lustig, L. R.; Giacomini, K. M. *J. Neurosci.* **2010**, *30*, 9500.
35. Thomas, A. J.; Hailey, D. W.; Stawicki, T. M.; Wu, P.; Coffin, A. B.; Rubel, E. W.; Raible, D. W.; Simon, J. A.; Ou, H. C. *J. Neurosci.* **2013**, *33*, 4405.
36. Dulon, D.; Zajic, G.; Aran, J. M.; J., S. *J. Neurosci. Res.* **1989**, *24*, 338.

37. Luedtke, N. W.; Carmichael, P.; Tor, Y. *J. Am. Chem. Soc.* **2003**, *125*, 12374.
38. Kirk, S. R.; Luedtke, N. W.; Tor, Y. *J. Am. Chem. Soc.* **2000**, *122*, 980.
39. Grote, J.; Himmelsbach, R.; Johnson, D. *Tetrahedron Lett.* **2012**, *53*, 6751.
40. Myrdal, S. E.; Johnson, K. C.; Steyger, P. S. *Hear. Res.* **2005**, *204*, 156.
41. Myrdal, S. E.; Steyger, P. S. *Hear. Res.* **2005**, *204*, 170.
42. Wang, Q.; Steyger, P. S. *J. Assoc. Res. Otolaryngol.* **2009**, *10*, 205.
43. Dai, C. F.; Mangiardi, D.; Cotanche, D. A.; Steyger, P. S. *Hear. Res.* **2006**, *213*, 64.
44. Steyger, P. S.; Peters, S. L.; Rehling, J.; Hordichok, A.; Dai, C. F. *J. Assoc. Res. Otolaryngol.* **2003**, *4*, 565.
45. Schacht, J. *Arch. Otorhinolaryngol.* **1979**, *224*, 129.
46. Williams, S. E.; Zenner, H. P.; Schacht, J. *Hear. Res.* **1987**, *30*, 11.
47. Zheng, J.; Dai, C.; Steyger, P. S.; Kim, Y.; Vass, Z.; Ren, T.; Nuttall, A. L. *J. Neurophysiol.* **2003**, *90*, 444.
48. Karasawa, T.; Wang, Q.; Fu, Y.; Cohen, D. M.; Steyger, P. S. *J. Cell Sci.* **2008**, *121*, 2871.
49. Havekes, R.; Nijholt, I. M.; Visser, A. K.; Eisel, U. L.; Van der Zee, E. A. *Neurobiol. Learn. Mem.* **2008**, *89*, 595.
50. Farris, H. E.; LeBlanc, C. L.; Goswami, J.; Ricci, A. J. *J. Physiol. (Oxford, U. K.)* **2004**, *558*, 769.
51. Chung, M. K.; Guler, A. D.; Caterina, M. J. *Nat. Neurosci.* **2008**, *11*, 555.
52. Jara-Oseguera, A.; Llorente, I.; Rosenbaum, T.; Islas, L. D. *J. Gen. Physiol.* **2008**, *132*, 547.
53. Moiseenkova-Bell, V. Y.; Stanciu, L. A.; Serysheva, II; Tobe, B. J.; Wensel, T. G. *Proc. Natl. Acad. Sci. U. S. A.* **2008**, *105*, 7451.
54. Shigematsu, H.; Sokabe, T.; Danev, R.; Tominaga, M.; Nagayama, K. *J. Biol. Chem.* **2010**, *285*, 11210.

55. Banke, T. G.; Chaplan, S. R.; Wickenden, A. D. *Am. J. Physiol. Cell Physiol.* **2010**, 298, C1457.
56. Jiao, G. S.; Castro, J. C.; Thoresen, L. H.; Burgess, K. *Org. Lett.* **2003**, 5, 3675.
57. Crich, D.; Sana, K. *J. Org. Chem.* **2009**, 74, 7383.
58. Sibrian-Vazquez, M.; Jensen, T. J.; Fronczek, F. R.; Hammer, R. P.; Vicente, M. G. H. *Bioconjug. Chem.* **2005**, 16, 852.
59. Belov, V. N.; Bossi, M. L.; Folling, J.; Boyarskiy, V. P.; Hell, S. W. *Chemistry* **2009**, 15, 10762.
60. Read, M. W.; Escobedo, J. O.; Willis, D. M.; Beck, P. A.; Strongin, R. M. *Org. Lett.* **2000**, 2, 3201.
61. Ghorai, M. K.; Nanaji, Y.; Yadav, A. K. *Org. Lett.* **2011**, 13, 4256.
62. Bower, F. J. S., P. Gallagher, T. **2007**, 5, 143.
63. Hsieh, J.-C.; Cheng, A.-Y.; Fu, J.-H.; Kang, T.-W. *Org. Biomol. Chem.* **2012**, 10, 6404.
64. Shen, Y.; Hou, S.; Yu, Y.; Zhao, L.; Xu, H.; Zhang, Y.; Anyang Institute of Technology, Peop. Rep. China . 2012, p 12pp.
65. Acker, T. M.; Khatri, A.; Vance, K. M.; Slabber, C.; Bacsá, J.; Snyder, J. P.; Traynelis, S. F.; Liotta, D. C. *J. Med. Chem.* **2013**, 56, 6434.
66. Dong, G.; Wang, S.; Miao, Z.; Yao, J.; Zhang, Y.; Guo, Z.; Zhang, W.; Sheng, C. *J. Med. Chem.* **2012**, 55, 7593.
67. Sun, M.; Ma, Y.-N.; Li, Y.-M.; Tian, Q.-P.; Yang, S.-D. *Tetrahedron Lett.* **2013**, 54, 5091.
68. Vogel, A. I. F., B. S.; Hannaford, A. J.; Smith, P. W. G. ;Tatchell, A. R. *Textbook of practical organic chemistry*; 5th ed.; Prentice Hall: New York, 1996.
69. Susic, I.; Barreateau, H.; Simcic, M.; Sink, R.; Cesar, J.; Zega, A.; Grdadolnik, S. G.; Contreras-Martel, C.; Dessen, A.; Amoroso, A.; Joris, B.; Blanot, D.; Gobec, S. *Eur. J. Med. Chem.* **2011**, 46, 2880.
70. Keana, J. F. W.; Ordentlich, P.; Goodenow, R.; Syndax Pharmaceuticals, Inc., USA . 2009, p 166pp.

71. Akhavan-tafti, H.; Eickholt, R. A.; Handley, R. S.; Lumigen, Inc., USA . 2001; Vol. US 2001/0031869A1.
72. Jiang, M.; Wang, Q.; Karasawa, T.; Koo, J. W.; Li, H.; Steyger, P. S. *PLoS ONE* **2014**, 9, e108941.
73. Ou, H.; Simon, J. A.; Rubel, E. W.; Raible, D. W. *Hear. Res.* **2012**, 288, 58.
74. Whitfield, T. T. *J. Neurobiol.* **2002**, 53, 157.
75. Ernest, S.; Rauch, G. J.; Haffter, P.; Geisler, R.; Petit, C.; Nicolson, T. *Hum. Mol. Genet.* **2000**, 9, 2189.
76. Ginos, J. Z.; Cooper, A. J.; Dhawan, V.; Lai, J. C.; Strother, S. C.; Alcock, N.; Rottenberg, D. A. *J. Nucl. Med.* **1987**, 28, 1844.
77. Ning, S.; Yu, N.; Brown, D. M.; Kanekal, S.; Knox, S. J. *Radiother. Oncol.* **1999**, 50, 215.
78. Ekborn, A.; Lindberg, A.; Laurell, G.; Wallin, I.; Eksborg, S.; Ehrsson, H. *Cancer Chemother. Pharmacol.* **2003**, 51, 36.
79. Baldew, G. S.; Volkers, K. J.; De Goeij, J. J.; Vermeulen, N. P. *J. Chromatogr.* **1989**, 491, 163.
80. Safaei, R.; Katano, K.; Larson, B. J.; Samimi, G.; Holzer, A. K.; Naerdemann, W.; Tomioka, M.; Goodman, M.; Howell, S. B. *Clin. Cancer Res.* **2005**, 11, 756.
81. Heetebrij, R. J.; Talman, E. G.; Von Velzen, M. A.; Von Gijlswijk, R. P. M.; Snoeijers, S. S.; Schalk, M.; Wiegant, J.; Von der Rijke, F.; Kerkhoven, R. M.; Raap, A. K.; Tanke, H. J.; Reedijk, J.; Houthoff, H. J. *Chembiochem* **2003**, 4, 573.
82. Dai, C. F.; Steyger, P. S. *Hear. Res.* **2008**, 235, 114.
83. Benoist, E.; Loussouarn, A.; Remaud, P.; Chatal, J.-F.; Gestin, J.-F. *Synthesis* **1998**, 1113.
84. Molenaar, C.; Teuben, J. M.; Heetebrij, R. J.; Tanke, H. J.; Reedijk, J. *J Bio Inorg Chem* **2000**, 5, 655.
85. Gale, J. E.; Marcotti, W.; Kennedy, H. J.; Kros, C. J.; Richardson, G. P. *J. Neurosci.* **2001**, 21, 7013.
86. Knox, R. J.; Friedlos, F.; Lydall, D. A.; Roberts, J. J. *Cancer Res.* **1986**, 46, 1972.

87. Thomas, J. P.; Lautermann, J.; Liedert, B.; Seiler, F.; Thomale, J. *Mol. Pharmacol.* **2006**, *70*, 23.
88. Qaddoumi, I.; Bass, J. K.; Wu, J.; Billups, C. A.; Wozniak, A. W.; Merchant, T. E.; Haik, B. G.; Wilson, M. W.; Rodriguez-Galindo, C. *J. Clin. Oncol.* **2012**, *30*, 1034.
89. Karasawa, T.; Sibrian-Vazquez, M.; Strongin, R. M.; Steyger, P. S. *PLoS ONE* **2013**, *8*, e66220.
90. Hall, J. R.; Appleton, T. G. *Inorg. Chem.* **1971**, *10*, 1717.

**APPENDIX A: ^1H NMR, ^{13}C NMR AND MS SPECTRA FOR SELECTED
COMPOUNDS FROM CHAPTER 1**

^1H NMR of compound 2.12

^{13}C NMR of compound 2.12

2010101108 #6-49 RT: 0.04-0.40 AV: 44 NL: 1.03E7
T: FTMS + p ESI Full ms [100.00-1207.87]

MS of compound 2.12

¹³C NMR of compound 2.13

MS of compound 2.13

¹H NMR of compound 2.6

¹³C NMR of compound 2.6

MS of compound 2.6

¹H NMR of compound 2.19

¹³C NMR of compound 2.19

MS of compound 2.19

¹H NMR of compound 2.21

¹³C NMR of compound 2.21

MS of compound 2.21

^1H NMR of compound 2.7

MS of compound 2.7

¹H NMR of compound 2.43

¹³C NMR of compound 2.43

MS of compound 2.43

^1H NMR of compound 2.44

¹³C NMR of compound 2.44

MSR of compound 2.44

¹H NMR of compound 2.40

¹³C NMR of compound 2.40

MS of compound 2.40

¹H NMR of compound 2.34

^{13}C NMR of compound 2.34

MS of compound 2.34

¹H NMR of compound 2.33

¹³C NMR of compound 2.33

MS of compound 2.33

¹H NMR of compound 2.32

¹³C NMR of compound 2.32

MS of compound 2.32

¹H NMR of compound 2.45

¹³C NMR of compound 2.45

MS of compound 2.45

¹H NMR of compound 2.46

¹³C NMR of compound 2.46

MS of compound 2.46

¹H NMR of compound 2.8

¹³C NMR of compound 2.8

MS of compound 2.8

APPENDIX B: ^1H NMR, ^{13}C NMR, ^{195}Pt AND MS SPECTRA FOR SELECTED COMPOUNDS FROM CHAPTER 4

^1H NMR of compound 4.5

^{195}Pt NMR of compound 4.5

^1H NMR of compound 4.1

^{13}C NMR of compound 4.1

^{195}Pt NMR of compound 4.1

MS of compound 4.1

09112501 #24-36 RT: 0.20-0.31 AV: 13 NL: 1.07E6
T: FTMS + p ESI Full ms [100.00-1200.00]

MS of compound 4.2